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ABSTRACT 
 
Jennifer Bushman Gilner: Enrichment of Therapeutic Hematopoietic Stem Cell Populations 
from Embryonic Stem Cells. 
(Under the direction of Suzanne Kirby, MD, PhD) 
 
Embryonic Stem Cells (ESC) serve as a versatile and infinite source of primitive stem 
cells of any developmental lineage, made readily available for study or therapeutic 
application.  The hematopoietic lineage in particular may benefit from such a level of 
accessibility since therapeutic applications from conventional sources of hematopoietic stem 
cells (HSC) are often limited by the inability to isolate or expand sufficient numbers of cells.  
However, the potential of alternative ESC-derived generation of HSC has not yet been 
fulfilled.  Our fundamental goal in the work presented in this dissertation was to define and 
characterize a method for the isolation of transplantable HSC differentiated from ESC.  Our 
initial study was designed to isolate early hematopoietic progenitors based on flow 
cytometric sorting of cells expressing a lineage-restricted fluorescent transgene.  However, 
incomplete genetic regulation of the transgene at the necessary stage of differentiation 
precluded its use as a molecular marker of HSC.  We then conducted studies in an adult 
source of HSC (i.e. bone marrow) to further characterize a stem cell enrichment method that 
separates a population of cells based on efflux of the DNA-binding fluorescent dye Hoechst 
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33342 (Side Population cells, SP).  Our findings demonstrate that within the SP, the exposure 
of cells to commonly used cell surface marker antibodies can reduce the engraftment of HSC.  
Returning to our original goal of isolating ESC-derived HSC, we applied the SP sorting 
method to early stage embryoid bodies (EBs) differentiated from ESC.  Our results show that 
the SP from early EBs contains long-term repopulating hematopoietic stem or progenitor 
cells, as evidenced by sustained (>16 weeks) lympho-myeloid engraftment of transplanted 
recipients.  Furthermore, we have found that inclusion of a truncated erythropoietin receptor 
transgene in ESC used to derive the graft can improve the efficiency of transplantation in a 
ligand-dependent fashion.  In summary, we have employed genetic and cell sorting 
techniques to successfully isolate and expand a population of HSC differentiated from ESC, 
and these studies may be useful in the design of future therapeutic applications from 
embryonic stem cells. 
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Chapter 1 LITERATURE REVIEW 
A. HEMATOPOIETIC STEM CELLS 
Defining the Phenotype of Hematopoietic Stem Cells— Hematopoietic stem cells 
(HSC) are functionally defined by their ability to both self-renew and differentiate into all 
lineages of the hematopoietic system (Fig. 1-1).  Efficient isolation and manipulation of this 
rare cell population has important implications in both basic research and clinical use.  Over 
the past several decades, many groups have sought to phenotypically define and purify long-
term repopulating pluripotent hematopoietic stem cells.  Protocols for the enrichment of HSC 
are based on: cell density [1, 2]; lectin binding [1]; dye exclusion [3, 4]; resistance to 
cytotoxic drugs, e.g. 5-fluorouracil [5-7]; adherence to plastic [8]; and, most commonly, 
expression of various combinations of cell surface antigens [9-16] (see also Table 1.1).  
Isolation of highly purified cells is critical for identifying the unique molecular mechanisms 
controlling HSC self-renewal and differentiation.  Understanding the mechanisms for 
maintaining stem cell properties may improve our ability to manipulate and potentially 
expand HSC without losing their developmental potential.  Furthermore, a precise definition 
of the HSC phenotype will facilitate the most efficient purification of therapeutic cells for 
transplantation. 
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Figure 1-1 The Hematopoietic Stem Cell (HSC) gives rise to all lineages of the hematopoietic system. 
Abbreviations: HPC, hematopoietic progenitor cell; CMP, common myeloid progenitor; CFU-S, spleen colony 
forming unit; CLP, common lymphoid progenitor; CFU-GEMM, colony forming unit-granulocyte, erythrocyte, 
monocyte, megakaryocyte; CFU-GM, colony forming unit-granulocyte, macrophage, NK cell, natural killer cell 
This figure reprinted with permission from original creator Dr. M. William Lensch, originally published at: 
http://daley.med.harvard.edu/assets/Willy/Willy_noframes.htm 
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Table 1.1 Methods used for isolation and enrichment of hematopoietic stem cells (HSC) from whole bone marrow (WBM) 
HSC PHENOTYPE RELATIVE % OF WBM 
ENRICHMENT OF 
CFU-S (D12) 
ENRICHMENT OF 
RADIOPROTECTION 
ENRICHMENT OF LT 
REPOPULATION 
(WBM=1 IN 100,000) 
REFERENCE 
Low density, bind WGA, 
H-2K+ nr 135-fold 180-fold nr [1] 
Linneg 10-15% (5%b) nr nr nr 
a) [9] 
b) [12] 
Thy-1loLinneg 0.1-0.2% 200-fold nr nr [9] 
Thy-1loLinnegSca-1+ 0.05% 1000-fold 1000-2000-fold (30 cells radioprotect) 2000-3000-fold
b a) [10] b) [17]. 
c-kit+ 5% nr nr nr [18] 
LinnegSca-1+c-Kit+ 
(SKL) 
0.08% (80% are CFU-S) 100 cells neededb 
100 cells rescue/reconst. 
(1000-2000-fold), 1 in 30 is 
CLTRb 
a)[11] 
b) [19] 
Rhodamine123neg 
(WGA+, 15-1.1neg) 0.25% nr 30 cells radioprotect 1200-2000-fold [4] 
LinnegSca-1+c-Kit+CD38+ 0.01% CFU-S are defined by CD38neg/low fraction nr 
1 in 13 – 1 in 20 
 [12] 
LinnegSca-1+c-
Kit+CD34neg 0.004% 1.6% per 200 cells nr 
Single cell in 21% of 
recipients [13] 
Hoechstlo (SP cells) 0.05-0.1% 200-fold 300-fold 1000-fold [3] 
Thy-1loLinnegSca-1+c-Kit+ 
(KTSL) 0.007% 1 in 61 cells nr 
80% of single cells are LT 
multipotent [14] 
CCE-25 (small, low 
density), c-kitneg nr nr nr nr [2] 
Thy-1loLinnegSca-1+c-Kit+ 
Flk-2neg 0.002% nr nr nr [15] 
Hoechstlo(SP), Endoglin+ 0.01% (20% of sp) nr nr Enriches LTR 5-fold over SP alone [16] 
nr: not reported; CFU-S: colony forming unit – spleen; LTR: long-term repopulation; SP: side population; WGA: wheat germ agglutinin; CLTR: competitive long-term 
repopulation 
 4
Transplantation and Therapeutic Obstacles— Hematopoietic stem cell (HSC) 
transplantation has curative potential for many disease states, including hematopoietic or 
solid malignancies, congenital disorders, acquired bone marrow failure syndromes, and 
autoimmune diseases [20].  Currently, sources of cells for transplantation in humans are 
limited to the adult stem cell compartments in the bone marrow (BM), peripheral blood, and 
umbilical cord blood (UCB).  There are three major obstacles to the success of 
transplantation therapy using these HSC sources.  First, long-term repopulating 
hematopoietic stem cells are rare, so cell numbers are often limiting.  Moreover, attempts to 
expand stem cell numbers ex vivo have been largely unsuccessful, resulting in loss of 
multilineage differentiation potential of the cells [21-23].  Lastly, the immunologic 
interaction between the donor and recipient cells following transplantation can lead to graft 
rejection or graft-versus-host disease, which may be a lethal complication of therapy [24].  
These issues are exacerbated in the use of hematopoietic stem cells for gene therapy 
applications, where therapeutic (gene-corrected) cell numbers are critically low at the outset 
[25].  In addition, commonly employed methods of isolation or enrichment of HSC involving 
antibodies to cell surface markers may compromise the normal physiology of the cells, 
thereby reducing the effective cell number even further (discussed in Chapter 3).  
Expansion of Hematopoietic Stem Cells— Initial approaches to expand HSC in vitro 
used various cytokine cocktails or co-culture with stromal cell lines (reviewed in [26]).  
These techniques have been deemed generally unsuccessful due to loss of repopulation 
potential [23] or homing ability of the cells [21].  An alternative approach has been through 
viral-mediated introduction of transgenes, such as genes that confer resistance to cytotoxic 
drugs like methotrexate [27], or genes that encode for transcription factors involved in cell 
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proliferation like Gata-3 [28].  Undesirable side effects of the selective agents for drug-
resistance transgenes limit their use in non-malignant disease.  Regarding the transcription 
factor approach, Hoxb4 emerged as a promising target for HSC expansion [29].  However, 
further studies have shown that prolonged expression of Hoxb4 compromises differentiation 
of HSC to the lymphoid lineage [30-32].  Furthermore, the long-term effects of any 
transcription factor gene overexpression include the potential for malignant transformation.  
Our laboratory has had a long-standing interest in hematopoietic stem cell expansion through 
the use of transgenic expression of growth factor receptors.  These receptors can serve as 
“non-toxic” transgenes, which optimally would give a benign and controllable expansion 
advantage to HSC without permanently altering the functions or developmental potential of 
the cells. 
B. USE OF A TRUNCATED ERYTHROPOIETIN RECEPTOR AS A BENIGN AND CONTROLLABLE 
TRANSGENE FOR STEM CELL EXPANSION 
Function and Structure of the Erythropoietin Receptor (EpoR)— As multipotent 
hematopoietic stem cells differentiate, erythroid progenitor cells up-regulate the lineage-
specific erythropoietin receptor (EpoR), which confers responsiveness to the cytokine growth 
factor erythropoietin (epo) [33].  The peak of EpoR expression and epo responsiveness 
occurs in relatively mature precursors, which are termed colony forming units-erythroid 
(CFU-E) in ex vivo assays [33, 34].  Epo binding leads to homodimerization of the EpoR, 
which initiates intracellular signaling pathways that regulate survival, proliferation and 
differentiation of the committed erythroid progenitors [35-37]. 
The EpoR is a member of the hematopoietin receptor superfamily, which is itself a 
subgroup of the type 1 cytokine receptor family.  Members of this family have a conserved 
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200 amino acid extracellular region consisting of an N-terminal domain with four conserved 
cysteine residues, and a C-terminal domain containing a Trp-Ser-X-Trp-Ser motif (WSXWS 
motif, where X represents any amino acid) (Fig. 1-2).  Each of the family members also has a 
single transmembrane-spanning region.  Ligand binding leads to rapid tyrosine 
phosphorylation of the cytoplasmic tail as well as associated signaling molecules, despite the 
fact that none of the receptors in this family possess intrinsic tyrosine kinase activity [38-41].   
Signal Transduction from the EpoR— In the case of the EpoR, signaling pathways 
that have been implicated in the response to ligand binding include the Ras/mitogen activated 
protein kinase (MAPK) pathway, the phosphatidylinositol 3 kinase (PI3K) pathway (either 
directly or through the adapter proteins insulin receptor substrate (IRS-) 1 or 2), and the 
Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway (reviewed 
in [42]).  However, a recent paper from Pelletier, et al. provides strong evidence based on the 
systematic analysis of over 40 mutant receptors that Jak2 is the sole direct signaling molecule 
downstream of EpoR required for biological activity [43].  Jak2 binding and activation by the 
EpoR requires two large domains in the membrane-proximal region, including the conserved 
Box1 and Box2 motifs as well as a glycine residue that is highly conserved amongst cytokine 
receptors.  Another key feature of the EpoR cytoplasmic domain is the presence of eight 
tyrosine residues – most or all of which are phosphorylated following ligand binding [44].  
The receptor can still transduce a proliferative signal when all eight tyrosine residues are 
mutated or removed, and importantly, removal of seven of the eight residues results in 
increased sensitivity of the receptor to epo [45]. 
Utility of a Truncated EpoR (tEpoR) Transgene— Previous studies in our laboratory 
explored the use of a truncated (epo-hypersensitive) mutant of the murine EpoR as a 
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transgene to impart a controlled proliferative advantage to hematopoietic stem cells both in 
vitro and in vivo.  The mutant receptor used in these studies (as well as further work to be 
described in Chapter 4 of this dissertation) has a carboxy-terminal 91-amino acid truncation, 
and will be referred to as tEpoR [45, 46] (see also Fig. 1-2).  Transgenic mice were generated 
by targeting the tEpoR to the hypoxanthine phosphribosyl transferase Hprt locus via 
homologous recombination in embryonic stem cells.  The mice are healthy with no overt 
hematologic phenotype in the absence of exogenous epo administration.  Treatment of these 
mice with epo results in the in vivo expansion of multipotent hematopoietic cells.  
Furthermore, the addition of epo to in vitro Dexter-type long term cultures of bone marrow 
cells from tEpoR transgenic mice results in the exponential expansion of trilineage 
hematopoiesis that can be maintained nearly twice as long as that from wild type bone 
marrow [46].  Competitive transplantation assays of tEpoR transgenic bone marrow proved 
that in the presence of exogenous epo, the tEpoR facilitates hematopoietic stem cell 
transplantation without stem cell depletion or malignant transformation [47].  Recently, a 
research group in Italy has further tested the utility of the same tEpoR transgene in the setting 
of viral transduction of both murine and human hematopoietic cells [48].  Consistent with the 
previous results from tEpoR transgenic mice, retrovirally transduced murine HSC acquired a 
repopulation advantage, and steady-state hematopoiesis in grafted recipients was unaffected 
as long as receptor levels were maintained at paraphysiological levels.  Lentiviral tEpoR 
transgene transduction of human cord blood-derived CD34+ cells led to expanded clonogenic 
capacity in vitro as well as significant increases in the ability of tEpoR transgenic cells to 
repopulate immunodeficient mice in a xenotransplantation model [48].  Together these 
studies establish the tEpoR as a transgene capable of conferring a benign, controllable 
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proliferation advantage to hematopoietic stem cells in multiple settings, which may be useful 
for the isolation, expansion, and gene therapy of HSC. 
 
Figure 1-2 Schematic of the full-length and truncated Erythropoietin Receptors (EpoR and tEpoR) 
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C. DEVELOPMENTAL HEMATOPOIESIS IN THE MOUSE EMBRYO 
Gastrulation to Blood Formation— In the developing embryo, the process of 
gastrulation establishes the body plan of the organism through the formation of the three 
primary germ layers: endoderm, ectoderm and mesoderm.  In the mouse this process begins 
approximately at embryonic day 6.5 (E6.5) [49].  The hematopoietic lineage arises out of the 
mesoderm layer through a common progenitor cell for endothelial and hematopoietic 
lineages, termed the hemangioblast [50].  The T-box transcription factor gene Brachyury (T) 
serves as a master regulator of genes required for the formation and differentiation of the 
mesoderm layer [51].  Molecular illumination of the mesoderm  using a green fluorescent 
protein targeted to the T locus in combination with in vitro culture assays and gene 
expression profiling have defined the precise stage and localization of hemangioblastic 
commitment in the developing embryo [50].  A subset of mesoderm cells in the posterior 
primitive streak (a transient embryonic structure central to gastrulation [51]) demonstrate 
hemangioblast commitment through upregulation of a gene encoding the vascular endothelial 
growth factor (VEGF) receptor fetal liver kinase 1 (Flk-1) [50].  Genetic knock-out studies in 
embryonic stem cells and mice have established FLK1 as a molecular determinant of the 
hemangioblast [52] that likely functions by facilitating migration of committed progenitor 
cells to a hematopoietic-permissive environment [53].  Accordingly, FLK1+ primitive streak 
progenitors then migrate to the extraembryonic yolk sac, where the earliest hematopoietic 
and endothelial cells arise in the blood islands around E7.5 [54, 55]. 
Ontogenic Sites of Hematopoiesis— This earliest wave of hematopoiesis in the yolk 
sac is predominated by primitive erythroid cells, characterized by large size, nuclear retention 
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and expression of the embryonic form of hemoglobin [56].  Definitive hematopoiesis, which 
generates definitive erythroid cells expressing adult globin genes, myeloid, megakaryocyte 
and lymphoid cells, arises in the fetal liver around E9.5 [57].  The classical view of 
hematopoietic ontogeny supposed that the yolk sac served as the origin of hematopoietic 
cells, which upon the establishment of the circulation around E8.5 would seed the fetal liver 
as a site for hematopoietic expansion [58], followed by migration to the bone marrow as the 
final site of hematopoiesis shortly after birth [57].  However, grafting studies in avian 
embryos provided evidence of a separate hematopoietic site within the embryo proper [59, 
60], and in the mid 1990’s several publications established the region of the developing 
mouse known as the para-aortic splanchnopleura (P-Sp, E8.5-9.5) / aorta-gonad-mesonephros 
(AGM, E10.5-11.5) as an autonomous site of hematopoietic development [61-64].  In the 
ensuing years there has been an ongoing debate over the true source of the definitive 
hematopoietic stem cell that seeds the fetal liver and eventually serves as the source of bone 
marrow hematopoiesis throughout the life of the animal (reviewed in [65, 66]).  Initially, the 
requirement for repopulation of irradiated adult hosts deposed the theory of yolk sac origin 
for the definitive HSC [67, 68].  However, subsequent studies showed that exposure of yolk 
sac cells to a fetal liver environment or co-culture with AGM stroma could induce a 
presumed “maturation” in the cells that conferred repopulation ability [69, 70].  The most 
recent work in this field provides authoritative evidence, by way of an elegant inducible cell 
tracing method, that at least a portion of the definitive HSC of the adult mouse are indeed 
derived from Runx1-expressing yolk sac cells [71]. 
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D. EMBRYONIC STEM CELLS AS A MODEL OF HEMATOPOIETIC DEVELOPMENT 
General Features of Embryonic Stem Cells— Embryonic stem cell lines (ESC) are 
derived from the inner cell mass of the preimplantation blastocyst-stage embryo [72, 73].  
These cells represent an incredibly versatile biological tool in that they can be propagated 
indefinitely in culture while maintaining their totipotency.  Leukemia inhibitory factor (LIF) 
is required to maintain murine ESC in an undifferentiated state in culture, whereas 
withdrawal of LIF leads to formation of embryoid bodies (EB) and differentiation [74].  EB 
formation recapitulates the early processes of in vivo development into the three primary 
germ layers: endoderm, ectoderm, and mesoderm.  There have been reports of in vitro 
generation of multiple cell types from all three germ layers, and ESC can contribute to all 
cell types of an animal when re-introduced into a blastocyst-stage embryo [75].  The 
proliferation and differentiation capacities of ESC, combined with their versatility and 
relative ease of genetic manipulation make them an ideal source for cell-replacement 
therapies for many tissues and organs. 
Generation of Hematopoietic Tissues from ESC— The first indication that ESC might 
model the development of the hematopoietic system came with the report that, in the absence 
of exogenous growth factors (other than those provided by serum), cystic EBs reliably 
develop blood islands similar to the blood islands of the E7.5 yolk sac [76].  Since that time, 
extensive exploration of the hematopoietic potential of ESC has ensued, making the 
hematopoietic lineage the most extensively characterized lineage from in vitro differentiation 
cultures of ESC [77, 78].  There are two basic differentiation schemes that have been 
developed for the generation of hematopoietic tissues from ESC; one involves the formation 
of EBs [79], and the other involves co-culture of the cells with a stromal line called OP9 
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[80].  The OP9 co-culture system allows for more control over the presence of specific 
growth factors or other influential molecules [77], and has been particularly useful in the 
generation of lymphoid lineages from ESC [80, 81].  However, it can be difficult to separate 
the stromal cells away from the desired differentiated populations, and the three-dimensional 
cell-cell interaction afforded by the EB system is necessary for accurate recapitulation of the 
in vivo processes of hematopoietic development [77].  Through careful study of the 
molecular and cell surface phenotypes as well as the developmental potential of the cultured 
cells over time, Keller et al. have established an efficient and reproducible EB-based protocol 
for the generation of primitive (erythroid, macrophage) and early definitive (erythroid, 
macrophage, megakaryocyte, neutrophil and mast) hematopoietic cell types in culture [79, 
82, 83].  This differentiation protocol accurately mirrors the development of the 
hematopoietic system in vivo, as determined by gene expression [79, 84, 85], cell surface 
marker expression [86, 87], and kinetic analysis of lineage specification [88]. 
Advantages of Studying Hematopoietic Development in the ESC System— Because 
the ESC/EB differentiation system so closely recapitulates the developmental program of the 
early embryo, it has become a trusted model system for embryonic hematopoietic 
development.  Yet, as an in vitro system, it allows access to rare numbers of early embryonic 
cells and stages of development that are otherwise inaccessible in the embryo [79].  As a 
result, several molecular markers of embryonic hematopoietic progenitors which differ from 
known adult HSC markers have been identified, such as FLK1 [86], VE-cadherin [87], and 
CD41 [89-91].  In addition, isolation of the elusive bipotential precursor of hematopoietic 
and vascular tissues, the hemangioblast, was first achieved in the in vitro ESC differentiation 
system [92, 93].  It was primarily through the study of culture conditions and molecular 
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markers for this in vitro hemangioblast that the identification of the hemangioblast in the 
developing embryo was possible [50].  Furthermore, this in vitro system has been highly 
complementary to the animal models for several molecules whose function could not be 
specifically characterized in vivo because their loss or mutation caused too severe a 
phenotype (e.g. Gata-1 [94], Gata-2 [95], Vav [96, 97]).  The one area in which the ESC 
model system of hematopoiesis has not fulfilled its anticipated potential is in the derivation 
of transplantable HSC, which consequently is the underlying goal of the studies presented in 
this dissertation. 
E. EMBRYONIC STEM CELLS AS A SOURCE OF DIFFERENTIATED CELL TYPES FOR 
REPLACEMENT THERAPIES 
Therapeutic Promise of ESC— There is much excitement and anticipation regarding 
the therapeutic promise of ESC to treat pathologic conditions such as Parkinson’s, 
Alzheimer’s, diabetes, spinal cord injury, muscular dystrophy, and myocardial infarction.  
The media focus on these possibilities has been even greater since the isolation of human 
ESC lines in 1998 [98].  Recent reports demonstrate the isolation of transplantable ES-
derived cells of all of the following types: endodermal precursors [99], hepatocytes [100], 
insulin-producing cells [101], dopamine neurons [102-104], neural precursors [105], 
microglia [106], and oligodendrocytes [107].  This research has met with varying levels of in 
vivo functional success, but overall has yielded evidence of many anticipated as well as some 
surprising characteristics of ES-derived tissues, such as the ability of certain cell types to 
engraft across major MHC barriers [99, 108].  A recurring problem in many of these reports 
is the incidence of teratoma formation in recipient animals due to the heterogeneous nature of 
transplanted cell populations [75].  Therefore, it is critical that any ESC-based therapeutic 
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proposals address the issue of isolating the desired cell type away from contaminating 
undifferentiated cells that may produce teratomas [77]. 
Hematopoietic Stem Cells from Embryonic Stem Cells— Despite the ever-growing 
body of knowledge regarding hematopoietic development from ESC since the discovery of 
yolk sac-like structures in EBs twenty-two years ago [76], there have been only about a 
dozen reports of successful generation of transplantable ES-derived hematopoietic cell types 
(See Table 1.2).  Moreover, a recent review article suggested that numerous other studies 
along these lines have been conducted but not reported due to failure of engraftment of the 
cells [109].  Several of the earliest reports focused on the engraftment and/or functional 
maturation of lymphoid progenitor populations in vivo; thus the researchers either did not 
detect or did not assay for myeloid engraftment, and they did not conduct secondary 
transplants to test for self-renewal properties of engrafted populations [110-112].  The first 
group to report multilineage engraftment that was renewable in secondary transplants was 
Palacios et al. in 1995 [113].  In fact, this group saw the highest level of engraftment reported 
to date, with some recipients demonstrating complete replacement of their peripheral blood 
with donor-derived cells.  They were also the first group to report an enrichment protocol for 
the transplanted cells – specifically, a lineage depletion step using magnetic bead-conjugated 
antibodies to seven different lineage markers, followed by a flow cytometry sorting step to 
isolate P-glycoprotein-expressing, lineage-negative cells.  Despite the authors’ reported 
success with this method, there have been no reports from other laboratories confirming the 
utility of this methodology in the generation of HSC.  This lack of reproducibility may stem 
from the fact that certain culture conditions used in the differentiation of the cells in this 
report involve highly variable components that are not readily available to other researchers 
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(i.e. conditioned media designated “F” from a fetal liver stromal line and co-culture with the 
bone marrow stromal line RP010) [109, 113].   
Two other reports described the isolation and moderately successful engraftment of a 
phenotypically defined cell population prior to transplantation.  The first, from Potocnik et 
al., defined a long-term lymphoid progenitor population by the expression of the fetal liver 
primitive hematopoietic marker AA4.1 [114], as well as the lack of expression of the early B 
cell marker B220 [115].  These authors reported a relatively low level (<15%) of donor 
chimerism, but showed evidence of functional lymphoid engraftment, as measured by 
immunoglobulin production of B cells and antigen-induced proliferation of T cells.  The 
second phenotypic enrichment protocol involved the selection of cells expressing the stem 
cell factor receptor KIT in addition to the pan-hematopoietic marker CD45.  The results of 
this study were notable for the fact that the authors saw relatively high levels of donor 
engraftment (>45%), even in the case of major histocompatibility complex (MHC)-
mismatched mice.  Furthermore, engraftment was enhanced in mice who were transplanted 
via direct intra-femoral injection despite lower numbers of cells injected [108].  These results 
suggest that the developmentally immature status of cells derived from ESC may be 
advantageous from the perspective of immunologic permissibility, but also problematic due 
to a possible lack of homing molecules necessary for engraftment in adult recipients.   
A common condition to all of the preparations of ESC-derived HSC discussed so far 
is the prolonged maintenance of the cells in culture (7-30 days).  Some of these studies make 
mention of the inability to transfer cells from earlier timepoints or different culture 
conditions due to the formation of teratomas in recipient mice [108, 111].  One study that 
challenges these claims reports multilineage engraftment from whole populations of 
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disaggregated day 4 EBs [116].  However, these results have been strongly criticized for the 
nonspecific characterization of donor-derived populations (reporting of the lineages of 
engrafted cells was based on forward and side scatter profiles rather than specific molecular 
markers) [109]. 
The remaining published reports of transplantable HSC are derived from genetically 
modified ESC.  Several recent reports from Daley et al. illustrate a carefully planned 
approach to the derivation of definitive adult-repopulating HSC from ESC through the 
enforced activation so-called “homeotic selector” molecules [117] that may span the gap 
between primitive and definitive hematopoietic potential (i.e., HOXB4 [117], STAT5A 
[118], and CDX4 [119]).  These studies were spawned by the results of their initial 
demonstration of multilineage engraftment of HSC derived from ESC that had been 
retrovirally infected with the chronic myeloid leukemia-causative oncogene Bcr/Abl [120].  
The recipient mice in this primary study developed myeloproliferative disease due to 
oncogenic transformation of the graft.  Moreover, their conclusions supported the existence 
of an “embryonic HSC” with both primitive erythroid potential and adult lymphomyeloid 
potential, thereby strengthening the hypothesis that repopulation activity is a function of the 
developmental environment of the cell. 
Regardless of the extent of donor chimerism from ESC-derived hematopoietic cells, 
each demonstration of engraftment provides important insights into the derivation of HSC 
from ESC.  Careful integration of the molecular and physiological lessons learned from each 
of these studies will bring the field gradually closer to the realization of the full HSC-
producing potential of the ESC system. 
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Table 1.2 Summary of publications reporting the derivation of transplantable hematopoietic cells from embryonic stem cells 
 
Source Transgene 
Culture Conditions 
Graft Dose 
Engr. 
(%) in 
1o 
Txplts 
Engr. (%) 
in 2o 
Txplts 
Lymph
/ 
Myelo 
Teratoma 
or other 
malignancy 
Ref EBs? Stroma Cytokines Days in Culture 
“ES fetus” 
D11-30EB 
Oncogenes 
(retrovirus) Y None - 11-30 10
7 0-72 ND +/+ Y [121] 
Diffn 
Culture None N 
RP010 
(BM) 
IL3, IL6, 
IL7 25 2-10x10
5 Y 
(%NR) ND +/- N [110] 
D5-22EB None Y None - 5-22 0.8-36x105 ≤ 4 ND +/- N [111] 
Diffn 
Culture None Y ST2 (BM) 
IL3, IL7, 
EPO 21 1-5x10
5 Y ND +/- N [112] 
PgP+Linneg None N RP010 (BM) 
IL3, IL6, 
“F” 25 4-6x10
4 ≤ 100 Y (%NR) +/+ NR [113] 
D4EB None Y None - 4 10
6 (+5x105 
splenocytes) 
Y 
(%NR) ND +/+ NR [116] 
AA4.1+ 
B220neg None Y None - 15 1-5x10
4 ≤ 15 ND +/(+) NR [115] 
D5EB 
+culture BCR/ABL Y 
OP9 
(MCSFneg) 
IL3, IL6, 
SCF 30 4x10
6 20-55 Y (%NR) +/+ MPD [120] 
D6EB 
+culture HOXB4 Y 
OP9 
(MCSFneg) 
SCF, 
VEGF, 
TPO, FL 
30 2x106 ≤ 50 0-40 ±/+ NR [117] 
KIT+ 
CD45+ None N None 
SCF, IL3, 
IL6 7-10 1-10x10
5 45-90 ND +/+ Y/N [108] 
Diffn 
Culture 
STAT5A 
(constit) N 
OP9 
(MCSFneg) - 7 1-2x10
6 5-20 Y (transient) +/+ Y [122] 
D6EB 
+Culture iSTAT5A Y 
OP9 
(MCSFneg) 
SCF, 
VEGF, 
TPO, FL 
30 1.75x106 ≤ 1 ND +/+ Y [118] 
D6EB 
+Culture 
iCDX4 + 
HOXB4 Y 
OP9 
(MCSFneg) 
SCF, 
VEGF, 
TPO, FL 
30 2x106 35-65 20-80 +/+ NR [119] 
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Table 1.2 List of Abbreviations:  EB, embryoid body; Engr., engraftment (expressed as 
percent donor chimerism in peripheral blood); Lymph, lymphoid; Myelo, myeloid; ND, not 
done; Diffn, differentiation; EPO, erythropoietin; PgP, P-glycoprotein; “F”, conditioned 
media derived from the fetal liver stromal line FLS4.1 [123]; NR, not reported; MCSFneg, 
indicates that the OP9 stromal cell line does not express the macrophage-colony stimulating 
factor protein; SCF, stem cell factor; VEGF, vascular endothelial growth factor; TPO, 
thrombopoietin; FL, FMS-like tyrosine kinase 3 ligand; constit, constitutively activated; i, 
inducible expression system 
 
Chapter 2 SCL 3' ENHANCERS DO NOT RESTRICT TRANSGENE EXPRESSION 
WHEN TARGETED TO THE Hprt LOCUS OF EMBRYONIC STEM CELLS 
A. ABSTRACT 
The relative accessibility and ease of manipulation of embryonic stem cells (ESC) 
make them a potentially ideal source for the generation of long-term repopulating 
hematopoietic stem cells (HSC).  However, an incomplete understanding of the molecular, 
cellular and environmental factors involved in HSC differentiation has limited the efficient 
generation of ESC-derived HSC with a repopulation potential comparable to conventional 
(adult-derived) sources of long-term repopulating HSC (LTR-HSC).  A specific enhancer 
region downstream of the stem cell leukemia (Scl) gene has been used in murine models to 
direct the expression of several transgenes to embryonic sites of HSC formation, specifically 
to fetal and adult LTR-HSC.  Thus, we hypothesized that fluorescent transgene expression 
controlled by this Scl enhancer would facilitate the isolation of HSC derived from ESC in 
vitro differentiation.  Instead, we found that when targeted to the Hprt locus of murine ESC, 
neither the +19 nor the +18+19 Scl 3' enhancer sequence could properly restrict expression of 
the fluorescent transgene Venus.  We observed widespread ectopic expression of Venus in 
non-Scl-expressing cells in both undifferentiated ESC and differentiated embryoid bodies 
(EB) generated from cell lines targeted with Scl enhancer-containing Venus constructs.  
Furthermore, integration of an Scl enhancer-containing construct in the reverse orientation 
with respect to Hprt transcription resulted in more robust Venus expression than if the Venus 
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construct (with or without an Scl enhancer) was integrated in the forward orientation.  We 
noted some downregulation of Venus expression as the cells differentiated – particularly with 
the +18+19 enhancer element – which may indicate some later stage tissue-specific 
expression.  Nonetheless, our studies demonstrate that additional regulatory elements are 
necessary to restrict Venus expression from a strongly permissive locus such as Hprt in ESC.   
B. INTRODUCTION 
Flow cytometry is a powerful tool for the identification, selection, and separation of 
discreet cell populations from complex mixtures of cell types.  Traditional flow cytometry 
generally involves the use of fluorophore-conjugated antibodies directed against cell surface 
molecules to mark cell populations with known surface molecule profiles (reviewed in 
[124]).  Staining techniques have also been developed for intracellular molecules, however 
these protocols require fixation and permeabilization of the cells and thus cannot be used to 
separate living cell populations [125].  For cell populations that do not have unique cell 
surface molecules, surface marker genes can often be genetically encoded for specific 
expression within the cells of interest.  In recent years, the expanded repertoire of fluorescent 
molecule-encoding sequences has promoted combining flow cytometry with lineage-specific 
gene expression techniques.  Using fluorescent transgenes as marker genes allows for the 
quick and easy identification and isolation of living cell populations by fluorescence 
activated cell sorting (FACS).   
Embryonic stem cells are an excellent model system for exploring the full potential of 
lineage-restricted fluorescent transgenes.  These totipotent cells are relatively easy to 
manipulate genetically, and in vitro differentiation protocols have been established for 
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numerous cell lineages (reviewed in [126]).  Several groups have recently used ESC 
containing fluorescent transgenes to isolate endothelial [127, 128], cardiac [129, 130], neural 
[131] and endodermal [132] progeny after in vitro differentiation.  In this study, we generated 
multiple embryonic stem cell lines carrying the fluorescent marker transgene Venus under 
the control of different enhancer elements from the stem cell leukemia (Scl) gene locus.  
Previous studies have demonstrated in murine models that these enhancer elements are 
sufficient to restrict transgene expression to cells of the hematopoietic and vascular lineages, 
including long-term repopulating hematopoietic stem cells (HSC) [133-135].  We targeted 
the Venus constructs to a specific locus (Hprt) in the ESC to control transgene copy number 
and integration site as well as to facilitate the direct comparison of Venus expression between 
transgenic cell lines [136]. 
Contrary to the results in transgenic mouse models, we found that the 3' Scl enhancer 
elements +19 or +18+19 were not sufficient to restrict Venus expression in undifferentiated 
ESC or in early stages of differentiation from ESC.  These studies suggest that gene-targeted 
hematovascular-specific fluorescent transgene expression will require either additional cis-
acting regulatory elements from the Scl locus or transcriptional regulatory elements from a 
different gene locus. 
C. MATERIALS AND METHODS 
Venus Expression Constructs and Gene Targeting— A plasmid containing the Venus 
fluorescent transgene and SV40 polyadenylation signal was kindly provided by Dr. A. 
Miyawaki (RIKEN Brain Science Institute, Saitama, Japan) [137].  The fluorescent gene was 
expressed from the SV40 minimal promoter, and for lineage-restricted expression vectors the 
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Scl gene 3' regions +19 (644 bp) or +18+19 (1 kb) were used as regulatory enhancer elements 
(generous gifts from Dr. B. Göttgens, University of Cambridge, United Kingdom).  The Venus 
expression constructs were cloned into a modified version of the previously described Hprt 
targeting vector pSKB1 [138].  Targeting constructs were linearized with PmeI prior to 
electroporation.  Cell culture, electroporation and selection of ESC were carried out by the 
University of North Carolina Animal Models Core Facility using the method described by 
Bronson et al. [138].  The ESC line used in these studies is a subclone of E14TG2a, a cell line 
derived from 129/Ola mice with an ~50 kb deletion in its Hprt gene [139] (Fig. 2-1). 
In Vitro Differentiation— Undifferentiated embryonic stem cells were grown on 
gelatinized plates (0.1% gelatin, Sigma) in Glasgow Minimum Essential Medium (G-MEM, 
Gibco) supplemented with 500 U/mL ESGRO© (Millipore), 12% heat-inactivated ESC 
Qualified Fetal Bovine Serum (Gibco), 10 µM 2-mercaptoethanol (Sigma), 2 mM L-
glutamine (Invitrogen), 100 µM nonessential amino acids (Invitrogen), 1 mM sodium 
pyruvate (Invitrogen), 100 U/mL penicillin (Invitrogen), and 100 µg/mL streptomycin 
(Invitrogen).  Hematopoietic differentiation of targeted ESC lines was carried out following 
the published method of Keller et al [83].  Briefly, EBs were generated by plating ESC in 
ultra-low binding 6-well plates (Corning) at a cell density of 50,000 cells/mL for day 3 EBs 
or 10,000 cells/mL for day 6 EBs.  Differentiation medium consisted of Iscove-modified 
Dulbecco’s medium (Gibco) supplemented with 15% Hematopoietic Differentiation Fetal 
Bovine Serum (Stem Cell Technologies), 2 mM L-glutamine (Invitrogen), 450 µM 
monothioglycerol (Sigma), 500 µg/mL holo-transferrin (Roche), and 50 µg/mL ascorbic acid 
(Sigma).  Day 6 EB differentiation medium also included an additional 5% protein-free 
hybridoma medium (Invitrogen).   
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Flow Cytometric Analysis— Embryonic stem cells and embryoid bodies were 
disaggregated with 0.05% Trypsin / 0.02% EDTA (Gibco).  Disaggregated cells were 
analyzed for Venus (YFP) fluorescence on a FACScan (BD Biosciences) or CyAn (Dako 
Cytomation) cytometer using Cytomation Summit software.   
Microscopy of Targeted Cell Lines— Phase contrast and fluorescence microscopy of 
Venus-targeted undifferentiated ESC was carried out using an Olympus IMT-2 microscope.  
Digitized images were produced with an Optronics TAC470 camera and Scion Image 
software (NIH).  Confocal images of day 3 EBs were captured on an Olympus FV500 
microscope using a Zeiss 20X/0.5NA lens.  Venus fluorescence was monitored using a 515 
nm excitation laser and a 535-565 nm bandpass filter for emission.  Stacks of single optical 
sections were processed into a single z projection using IMAGEJ software (NIH).  
D. RESULTS 
Targeting Scl-Venus Transgene Constructs to the Hprt Locus of Embryonic Stem 
Cells— We generated multiple constructs designed to restrict the fluorescent transgene 
Venus to hematovascular progenitor cells (hemangioblasts) upon differentiation of ESC in 
vitro.  The 644 bp +19 Scl 3' enhancer element has been shown in transgenic mouse models 
to be sufficient to restrict transgene expression to hemangioblasts and their Scl-expressing 
progeny [135].  However, this minimal core enhancer has some dependence on integration 
site dependence for proper expression control, and it failed in directing β-galactosidase 
transgene expression to adult tissues (despite reliably directing a placental alkaline 
phosphatase transgene to adult tissues) [140].  In anticipation of similar expression fidelity 
issues in the ESC system, we also designed constructs incorporating a 1 kb fragment of the 
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+18+19 Scl 3' enhancer, which maintains proper Scl-controlled expression, but does not show 
integration site dependency (B. Göttgens, personal communication).  Importantly, all other 
transcriptional control elements (promoter, polyadenylation sequence) were identical to those 
used in previous mouse transgenic studies showing properly restricted transgene expression.  
We also made a Venus only construct with no Scl enhancer elements to serve as a positive 
control with unrestricted Venus transgene expression.  All Venus constructs are illustrated in 
Figure 2-1A.   
We chose to target the Venus transgene constructs to the Hprt locus of mouse ESC 
using the single-copy chosen site integration method described by Bronson, et al. [138] (Fig. 
2-1B).  This targeting strategy eliminates transgene expression variability based on copy 
number or site of integration and allows for direct comparison of transgene expression 
between different transgene constructs.  One important variable that remains when using this 
targeting method is the orientation of transgene construct integration with respect to the Hprt 
locus [141, 142].  Therefore, we designed two of our targeting constructs to direct Venus+19 
integration both the forward and reverse (-Rev) orientation with respect to the direction of 
Hprt gene transcription (directionality of transgene integration is indicated by the large grey 
arrows in Figure 2-1A).  Based on preliminary results demonstrating high-level unrestricted 
Venus expression from Venus+19-Rev targeted cells, as well as similar results from our 
collaborators in the laboratory of Dr. O. Smithies showing much stronger transgene 
expression in reverse-targeted ESC lines (D. Ciavatta and S. Hatada, personal 
communication), the remainder of our Venus constructs were only targeted in the forward 
orientation.
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Figure 2-1 Transgene constructs and gene targeting to the Hprt locus.  
A.) In all transgene constructs, the fluorescent protein gene Venus including the SV40 polyadenylation signal 
(solid yellow box) is driven by the SV40 minimal promoter (hatched box).  Black arrows indicate the start site 
and direction of transcription.  Open boxes labeled +18+19 (1 kb) or +19 (644 bp) represent the 3' Scl enhancer 
elements intended to restrict Venus expression to the normal Scl expression domain.  Large grey arrows indicate 
the direction of transgene transcription with respect to Hprt gene transcription after targeting. 
B.) (Top) The untargeted Hprt locus in the ESC line (E14Tg2a).  The dashed line within parentheses represents 
the ~50 kb deletion that removes the Hprt promoter and first two exons.  (Middle) The targeting construct 
includes a transgene from A.) and the missing promoter and exons to correct the Hprt gene, flanked by 
homologous sequences to direct recombination.  Solid lines represent mouse sequences, and open lines indicate 
that in the correcting DNA the HPRT promoter (Phum) and its first exon are derived from the human HPRT gene.  
(Bottom) Following HAT (hypoxanthine, aminopterine, thymidine) selection, only clones with a corrected Hprt 
locus, and thus an integrated transgene, will survive. 
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Scl-Venus Transgene Expression in Undifferentiated Embryonic Stem Cells— Much 
to our surprise, we saw widespread ectopic expression of the Venus transgene in 
undifferentiated ESC cultures from all targeted Scl-Venus cell lines.  The undifferentiated 
cells showed normal ESC morphology and growth patterns in culture (see phase images, Fig. 
2-2A), indicating that Venus expression did not have a detrimental effect on growth or 
maintenance of the ESC.  However, considering that Scl is not normally expressed until the 
specification of hemangioblast progenitors from mesodermal precursors, we expected a 
complete lack of Venus expression at the undifferentiated ESC stage in the Scl 3' enhancer-
containing clones [133].  On the contrary, nearly 100% of the cells from targeted ESC 
cultures display Venus fluorescence, as detected by flow cytometry, in comparison to 
untargeted ESC (Fig. 2-2, B and C).  In forward-targeted cell lines, Venus transgene 
expression in Scl 3' enhancer containing lines was nearly indistinguishable from the positive 
control Venus-only cell line, suggesting that the +19 and +18+19 enhancer elements exert no 
control over Venus expression in undifferentiated ESC when targeted to the Hprt locus.  
Furthermore, Venus expression from the Venus+19-Rev transgene (69.35±30.09) was more 
than 3-fold higher than expression from the Venus+19 transgene (21.3±12.53), indicating 
orientation-dependent effects on transgene expression. 
Scl-Venus Transgene Expression in Day 3 Embryoid Bodies— Targeted ESC lines 
were allowed to form embryoid bodies (EBs) in vitro, following the protocol described by 
the Keller et al. [82].  Using this differentiation scheme, multipotent hemangioblast 
progenitors are generated within the embryoid body after approximately 3 days of 
differentiation [92].  Our original goal in the creation of these ESC lines was to use Scl-
restricted Venus expression to isolate hematopoietic stem cells from ESC.  Thus, proper 
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Figure 2-2 Venus expression in targeted, undifferentiated Embryonic Stem Cell (ESC) lines.  
A.) Phase contrast images and fluorescence signal (pseudocolored yellow) from undifferentiated ESC cultures 
of cell lines targeted with the Venus+19 or Venus+19-Rev constructs, as indicated.  Note that both cell lines 
show Venus expression in undifferentiated ESC, which do not normally express Scl, and that the expression 
appears brighter in the Venus+19-Rev cells. 
B.) Flow cytometric verification of Venus expression in Venus+19 and Venus+19-Rev cells.  Nearly 100% of 
live cells from undifferentiated cultures of both cell lines show some level of Venus fluorescence, and 
expression is much higher in the Venus+19-Rev cell line. 
C.) Flow cytometric analysis of Venus fluorescence from targeted cell lines expressing Venus with no enhancer, 
the +19 enhancer, or the +18+19 enhancer, as indicated.  There is almost complete overlap of the three cell 
populations, suggesting that the two enhancer elements exert no influence over Venus expression in 
undifferentiated ESC. 
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transgene expression at this stage was critical to our objectives.  Unfortunately, day 3 
embryoid bodies from all Scl-Venus targeted ESC lines continued to show widespread 
ectopic expression of Venus (Fig. 2-3).  Confocal images of the 3-dimensional EBs 
illustrated fluorescent cells throughout the EBs, and as seen in the undifferentiated ESC, 
Venus expression was much brighter with the reverse-oriented transgene (Fig. 2-3A).  Flow 
cytometric analyses of trypsin-disaggregated day 3 EB cells confirmed that there was 
continued ectopic expression of Venus at this stage of differentiation, particularly from the 
Venus+19 transgene.  Interestingly, the Venus+18+19 transgene showed a small Venus-
negative population, indicating at least partial control of Venus expression by the larger 
enhancer element as the cells differentiated. 
Scl-Venus Transgene Expression in Day 6 Embryoid Bodies— Targeted ESC lines 
formed EBs as before and were allowed to differentiate for 6 days, at which point they 
contain multipotent hematopoietic progenitor cells of the myeloid and erythroid lineages 
[82].  EB cells were sampled every 24 hours during differentiation from day 3 to day 6 to 
track Venus transgene expression in the Venus+19 ESC line.  Consistent with the findings of 
slight Venus downregulation in day 3 EBs, Venus expression continued to drop dramatically 
as the cells differentiated up to day 6 (Fig. 2-4A).  The reduction in transgene expression was 
even more pronounced in Venus+18+19 cells, suggesting that the larger enhancer segment 
exerts more stringent control on Venus expression in later-stage EB cells.  In contrast, the 
Venus+19-Rev transgene was still very bright in approximately 100% of cells at this stage of 
differentiation, indicating that the +19 enhancer element cannot overcome orientation-related 
influences on transgene expression from the Hprt locus. 
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Figure 2-3 Venus expression in Embryoid Body (EB) cells after 3 days of differentiation.  
A.) Phase contrast images and z projections of confocal images of the fluorescence signal (pseudocolored 
yellow) from day 3 embryoid bodies differentiated from cell lines targeted with the Venus+19 or Venus+19-
Rev constructs, as indicated.  Note that nearly all cells within the embryoid bodies show Venus expression and 
that again the expression appears brighter in the Venus+19-Rev cells. 
B.) Flow cytometric analysis of Venus fluorescence from the day 3 embryoid bodies of cell lines expressing 
Venus with no enhancer, the +19 enhancer (For and Rev), or the +18+19 enhancer, as indicated.  While the 
embryoid body cells from the +19 enhancer lines are still nearly 100% Venus+ (and both brighter than the cells 
with Venus alone), the cells from the +18+19 enhancer line are beginning to show some downregulation of (or 
suppression of) Venus expression in a subpopulation of cells within the embryoid body. 
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Figure 2-4 Venus expression in Embryoid Body (EB) cells after up to 6 days of differentiation.  
A.) Progressive decline in Venus expression in Venus+19 embryoid body cells after 3, 4, 5, and 6 days of 
differentiation.  As the cells differentiate, the Venus+ population declines significantly, suggesting that in more 
differentiated cell types, the Scl enhancer element may exert some regulatory control over Venus expression. 
B.) Flow cytometric analysis of Venus fluorescence from the day 6 embryoid bodies derived from cell lines 
expressing each of the three Venus-Scl enhancer constructs.  Both the +19 and the +18+19 enhancer sequences 
appear to exert some control over Venus expression at this later stage, although the +18+19 enhancer is more 
stringent.  When targeted in the Reverse orientation, the +19 enhancer sequence is unable to restrict Venus 
expression, even in day 6 EBs. 
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E. DISCUSSION 
A major advantage of the embryonic stem cell system is that it allows access to and 
scalable production of rare or inaccessible cell populations.  We planned to take advantage of 
this system for the identification and subsequent isolation of hematopoietic stem cells (HSC) 
from murine ESC.  To that end, we hypothesized that lineage-restricted fluorescent transgene 
expression controlled by an enhancer element previously shown to direct transgene 
expression to long-term repopulating HSC [134] would facilitate FACS-based isolation of 
HSC from ESC.  However, to our surprise, the Scl 3' enhancer element was not sufficient for 
lineage restriction of fluorescent transgene expression in ESC when targeted to the Hprt 
locus. 
The transcriptional regulation of the Scl locus has been extensively characterized, 
resulting in the identification of five independent enhancers targeting expression to specific 
subdomains of normal Scl expression [133, 135, 143-145].  We were particularly interested 
in the 3' element that was shown to direct expression to hemagioblasts, hematopoietic stem 
and progenitor cells and endothelium [133-135].  This +18+19 enhancer element was 
originally characterized as a 5245bp fragment and the full-length enhancer has subsequently 
been used to direct HSC expression of multiple different transgenes in murine models [134, 
146-149].  The present study represents the first description of the activity of this Scl 3' 
enhancer region in ESC, and notably, we have only characterized two core elements (644 bp 
+19 and 1 kb +18+19) and not the full-length 5245 bp +18+19 enhancer.  Nonetheless, while 
these core elements have proven sufficient to restrict transgene expression to Scl-expressing 
cell populations in transgenic mice ([135, 140] and B. Göttgens, personal communication), 
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we found that they are unable to effect proper developmental restriction of transgene 
expression in the ESC system when targeted to the Hprt locus.  We demonstrate here that 
Hprt-targeted Venus transgene constructs express strongly in all cells of undifferentiated 
ESC cultures even in the presence of +18+19 (1 kb) or +19 (644 bp) Scl 3' enhancer 
elements.  This widespread ectopic transgene expression is gradually downregulated as the 
cells differentiate into embryoid bodies when the +18+19 enhancer is present, and to a lesser 
degree when the +19 enhancer is present, but only if it is targeted in forward orientation with 
respect to the Hprt locus.   
While the ESC/EB system recapitulates developmental processes in many ways 
(reviewed in [150]), there clearly are transcriptional control mechanisms responsible for 
maintaining pluripotency in ESC that are no longer active in the developing embryo [151].  
Thus, it stands to reason that transcriptional control elements which are sufficient to restrict 
transgene expression in whole mouse models may require additional cis-acting regulatory 
elements to effect similar lineage restriction in ESC.  This phenomenon has been described in 
the case of a murine fetal liver kinase-1 promoter/enhancer (Flk-1 p/e) element identified by 
Kappel et al. [152], which was shown to direct endothelial cell-specific expression in 
transgenic mice, but allowed ectopic transgene expression in undifferentiated ESC in two 
separate studies [128, 153].  In both cases, the ectopic activity was significantly reduced as 
the cells differentiated, which directly mirrors our findings with the Scl 3' enhancer elements.  
In the Flk-1 p/e studies, the authors were interested in studying terminally differentiated cell 
types from the ESC system, thus the ectopic transgene expression had been abolished in the 
developmental stage in which they needed to make use of the transgene.  In contrast, our 
study was intended to isolate a transient cell population known to exist in EBs between day 3 
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and 3.25 of differentiation [82].  At this stage of differentiation, EBs still contain many 
undifferentiated ESC, as evidenced by the ability to generate secondary EBs from cultures of 
dispersed day 3 primary EBs [82].  Therefore, widespread ectopic Venus expression in 
undifferentiated cells of the day 3 EBs precludes the use of the fluorescent transgene to 
isolate hemangioblasts or HSC at this stage, even if the Scl enhancer element properly 
restricts Venus expression in a subset of the cells. 
A recent paper by Szutorisz et al. [154] describes a proteasome-based mechanism for 
transcriptional control in ESC that likely explains the phenomenon of differential enhancer 
activity in transgenic mice versus ESC that was noted in the studies described in this chapter.  
Their work illustrates a model of proteasome recruitment to and subsequent degradation of 
preinitiation complexes that are not stabilized by tissue-specific activators.  This mechanism 
counteracts the permissive chromatin environment of ESC while maintaining pluripotency of 
the cells.  In our ESC lines, it is likely that the Scl enhancer elements we employed lack the 
sequences that would be targeted by the proteasome complex in the endogenous Scl locus to 
prevent transcription in ESC.  
In addition, it is possible that targeting the Scl-Venus transgenes to the Hprt locus 
may have exacerbated ectopic expression since it is a highly permissive locus that would not 
exert chromatin-based repression on the transgene.  However, several groups have 
successfully produced lineage-specific expression of transgenes targeted to the same locus 
[155-157].  Also, since expression from this locus is not developmentally controlled, the 
ectopic transgene expression should not change upon differentiation of the ESC, which was 
not the case in our transgenic lines.  On the other hand, the significant divergence in 
transgene expression in differentiated cells containing the Venus+19 transgene compared to 
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those containing the Venus+19-Rev transgene suggests that transgene orientation within the 
locus may influence ectopic expression.  Previous studies have shown that within a specific 
locus, divergent expression of two transcriptional units is more permissive than a convergent 
or tandem arrangement [141, 142], so forward integration of the Venus transgene may help 
minimize ectopic expression from the Hprt locus.   
In summary, lineage restriction of a fluorescent transgene for isolation of HSC from 
ESC may be possible with a few genetic modifications to the current approach.  In order to 
maintain the benefits of Hprt targeting, including single-copy insertion to a known locus with 
efficient selection of targeted clones, it will be necessary to incorporate additional cis-acting 
regulatory elements capable of restricting transgene expression in undifferentiated ESC.  A 
promising alternative approach has recently been described by members of the S. K. Bronson 
laboratory in which full bacterial artificial chromosomes (BACs) can be targeted as a single 
copy into the Hprt locus [158].   
Chapter 3 ANTIBODIES TO STEM CELL MARKER ANTIGENS REDUCE 
ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS 
Previously published as: Gilner JB, Walton WG, Gush K, and Kirby SL. Antibodies to stem 
cell marker antigens reduce engraftment of hematopoietic stem cells. Stem Cells. 
2007;25:279-288.  Copyright held by AlphaMed Press; reprinted with permission. 
A. ABSTRACT 
Hematopoietic stem cells (HSC) have enormous potential for use in transplantation 
and gene therapy.  However, the frequency of repopulating HSC is often very low; thus, 
highly effective techniques for cell enrichment and maintenance are required to obtain 
sufficient cell numbers for therapeutic use and for studies of HSC physiology.  Common 
methods of HSC enrichment use antibodies recognizing HSC cell surface marker antigens.  
Because antibodies are known to alter the physiology of other cell types, we investigated the 
impact of such enrichment strategies on the physiology and lineage commitment of HSC.  
We sorted HSC using a method that does not require antibodies: exclusion of Hoechst 33342 
to isolate side population (SP) cells.  To elucidate the effect of antibody binding on this HSC 
population, we compared untreated SP cells to SP cells treated with the Sca-1+c-Kit+Lin- 
(SKL) antibody cocktail prior to SP sorting.  Our findings revealed that HSC incubated with 
the antibody cocktail had decreased expression of the stem cell-associated genes c-Kit, Cd34, 
Tal-1, and Slamf1 relative to untreated SP cells or to cells treated with polyclonal isotype 
control antibodies.  Moreover, SKL antibodies induced cycling in SP cells and diminished 
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their ability to confer long-term hematopoietic engraftment in lethally irradiated mice.  Taken 
together, these data suggest that antibody-based stem cell isolation procedures can have 
negative effects on HSC physiology.   
B. INTRODUCTION 
While many hematopoietic stem cell enrichment methods depend on the use of 
antibody cocktails to surface marker antigens, an alternative enrichment method exploits the 
ability of HSC to exclude the supravital fluorescent dye Hoechst 33342.  This distinctive 
“side population” (SP) possesses both the phenotypic markers and the functional abilities of 
primitive stem/progenitor cells [3].  The dye exclusion-based approach is dependent on a 
functional property of HSC, whereas most of the antigens used in antibody-based enrichment 
schemes have been shown to be non-essential to HSC function [159-162].  In addition, 
expression of these antigens may vary with age [163], cell proliferation status [164], or may 
differ between species.  Potential additional advantages to the dye exclusion-based 
enrichment are: inclusion of facilitating cells for engraftment of HSC, inclusion of 
progenitors for other cell types such as endothelial cells, cost savings, and the avoidance of 
antibody-induced physiologic changes in the HSC.   
It is well documented that monoclonal antibodies may be used to activate or 
otherwise alter the homeostasis of certain cell types [165-173].  In hematopoietic cells, 
various monoclonal antibodies have been shown to induce cellular proliferation, 
differentiation, and lineage specification [165, 171]; induce cytokine secretion [166, 170] and 
apoptosis [167, 172]; and to activate cell signaling via tyrosine protein phosphorylation [168, 
169, 173].  Furthermore, studies using monoclonal antibodies against 
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glycosylphosphatidylinositol (GPI) anchored proteins revealed that members of this class of 
proteins share the biological property of inducing cellular growth, likely through association 
with Src family protein tyrosine kinases [174, 175].  This data may be particularly pertinent 
to HSC isolation, as Sca-1 (Ly6a) and Thy1 are two GPI-anchored proteins that are 
frequently used to enrich long-term repopulating cells via antibody labeling and FACS 
sorting.  Thus, we hypothesized that the antibody cocktails commonly used in HSC 
purification might alter the normal physiology of stem cells.   
In this study, we investigated the effects of antibodies to stem cell surface marker 
antigens on HSC by comparison of SP-sorted HSC from untreated murine bone marrow cells 
versus bone marrow cells from the same animals that had been incubated with the SKL 
antibody cocktail prior to SP sorting.  We observed significant changes in the expression of 
stem cell-related genes with SKL antibody treatment that appeared to correlate with a loss of 
functional repopulating stem cells, possibly by inducing HSC cycling, as has been previously 
reported [176].  Taken together, these results suggest that the antibodies used to label and 
sort HSC may alter their physiology, thereby effectively reducing the yield of actual long-
term repopulating HSC. 
C. MATERIALS AND METHODS 
Animals— C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) were 
maintained in the animal facility at the University of North Carolina, Chapel Hill, NC in 
accordance with IACUC standards.  All animals were housed in autoclaved, micro-isolator 
cages and supplied with irradiated mouse chow and sterile water ad libitum.  All mice used 
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were between 7 and 16 weeks of age at the initiation of the experiments, and mice were age-
matched within each experiment. 
For transplantation experiments, SP cells were isolated from the bone marrow of  B6 
mice expressing the enhanced GFP (eGFP) protein [177].  Bone marrow from B6.SJL-Ptprca-
Pepcb/BoyJ (CD45a) mice (Jackson Laboratory, Bar Harbor, ME) – which are congenic with 
B6 mice, carrying the SJL allele for CD45a – was used as a source of short-term engrafting 
cells. 
Preparation of Bone Marrow Cells— Mice were euthanized and femurs and tibias 
were removed.  The marrow cavities were flushed with either sterile HBSS+ (Hank’s 
Balanced Salt Solution (HBSS) with 2% fetal calf serum (FCS), 10 mM HEPES, 100 U/mL 
penicillin and 100 μg/mL streptomycin) or sterile IMDM media supplemented with 5% FCS, 
100 U/mL penicillin and 100 μg/mL streptomycin.  Cell suspensions were filtered through a 
cell strainer to remove debris. 
Hoechst 33342 Staining (+/- Antibody Staining) for SP Isolation— Bone marrow was 
harvested as above in cold HBSS+, and the resulting cell suspensions were centrifuged at 
1500 rpm (~600g) for 12 minutes at 4°C.  Cell pellets were resuspended in pre-warmed 
(37°C) RPMI medium containing 2% FCS, 10 mM HEPES, 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 5 μg/mL Hoechst 33342.  Total nucleated cells (TNC) were counted and 
brought to a final concentration of 1 x 106 TNC/mL.  Cell suspensions were incubated at 
37°C for 90 minutes and immediately centrifuged at 600g for 8 minutes at 4°C.  Cell pellets 
were resuspended in 1 mL ice-cold flow suspension buffer (HBSS containing 2% FCS, 10 
mM HEPES, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 μg/mL propidium iodide).  
For samples treated with SKL antibodies, cells were suspended in 1mL ice-cold HBSS+ and 
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stained for 30 minutes on ice with the antibodies described below. Cells were then washed 
once with an excess of ice-cold HBSS+ and resuspended in 1 mL ice-cold flow suspension 
buffer. 
Antibody Staining and FACS for SKL Isolation— Bone marrow was harvested as 
above and stained in a two-step procedure with FITC-conjugated c-kit (clone 2B8, 3.75 
μg/107 cells), biotinylated Sca-1 (clone E13-161.7, 3 μg/107 cells), and PE-conjugated 
lineage marker antibodies (CD3:145-2C11, B220:RA3-6B2, TER119, Mac-1:M1/70, and Gr-
1:RB6-8C5, 0.8 μg each/107 cells).  The initial immunostaining was followed by incubation 
with a secondary antibody conjugated to streptavidin-PE-Cy5.  (Antibodies were a gift from 
Dr. Lishan Su, UNC-Chapel Hill or purchased from Pharmingen, San Jose, CA).  All 
incubations were done on ice and washes in ice-cold buffers.  Aliquots of cells were stained 
individually for isotype controls. 
Fluorescence Activated Cell Sorting (FACS)— Cell sorting was performed on a dual 
laser Modular Flow (MoFlo) cytometer (Cytomation, Inc.).  For SP sorting, an Argon laser 
provided excitation of the Hoechst dye at 350 nm and emission was monitored 
simultaneously at 405 nm (blue fluorescence) and 670 nm (red fluorescence) for analysis.  SP 
cells were sorted based on the gate shown in Figure 3-2.  A small sample of cells was run 
back through the cytometer following each sort to check the purity of the SP sorting (Figure 
3-2, right panel).  For SKL sorting, excitation was provided by laser output at 488 nm and 
fluorescence emission was monitored as appropriate for each fluorochrome.  For RT-PCR 
analysis in SP compared to SKL studies, samples of 100 cells were sorted into 0.2 mL 
microfuge tubes containing 5 μL cell lysis buffer (Cells-to-cDNA kit, Ambion, Austin, TX), 
moved immediately to dry ice, then stored at -70°C.  For RT-PCR studies comparing 
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SP(+Ab) to SP(untreated), single cells or 20 cell pools were sorted (based on Hoechst dye 
exclusion, Figure 3-2) into 8-well mRNA Isolation GeneStrips containing 15 μL Working 
Lysis Buffer (RNAture, Irvine, CA), moved immediately to dry ice, then stored at -70°C.  
For transplantation experiments, defined numbers of SP cells (enough for final doses of 10, 
20 or 50 cells per animal) were sorted into sterile tubes containing sterile IMDM media 
supplemented with 5% FCS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10 μg/mL 
Gentamicin. 
Reverse transcription – polymerase chain reaction (RT-PCR)— For SP compared to 
SKL studies: Samples were lysed by heating to 80°C in a thermocycler block for 5 minutes 
and then cooled to 4°C.  DNase I (0.07 U/μL) treatment was performed to degrade genomic 
DNA in the samples.  Samples were incubated at 37°C for 30-45 minutes and then heated at 
75°C for 5 minutes to inactivate the DNase I.  Reverse transcription was performed by the 
protocol provided with the Cells-to-cDNA kit (Ambion, Austin, TX).  The resulting cDNA 
was aliquoted into 5 individual 0.2 mL PCR tubes and stored at -20°C until PCR was 
performed.  Amplification of specific genes was performed using enzymes and reagents 
supplied with the HotStarTaq Polymerase system (Qiagen). Table 3.1 lists all primers and 
PCR cycling conditions used.  cDNA from murine bone marrow nucleated cells was used as 
a positive control for expression of all genes except the endothelial growth factor receptors 
Kdr (Flk-1) and Tek (Tie-2); for these genes cDNA from the endothelial cell line PY4.1 was 
used as the positive control [178]. 
For SP(+Ab) compared to SP(untreated) studies: Cell lysates were allowed to 
hybridize to GeneStrips Hybridization Tubes (RNAture, Irvine, CA) for 90 minutes at room 
temperature, then washed three times with wash buffer.  Based on the solid-phase synthesis 
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protocol provided in the GeneStrips manual, cDNA was generated using SuperScript II 
Reverse Transcriptase (Invitrogen, Carlsbad, CA), dNTPs (Amersham Biosciences, 
Piscataway, NJ), and the immobilized poly(dT) on the Hybridization Tubes as primers.  
Since the synthesized cDNA was covalently linked to the GeneStrips tubes, several rounds 
(6-7) of PCR could be run on the same samples.  Following cDNA synthesis, each sample 
was tested for the presence of template using HPRT as an internal control.  Samples that 
tested negative for HPRT message were discarded, while samples that tested positive for 
HPRT were then assayed for other genes of interest.  Figure 3-1 shows an example of results 
for the HPRT RT-PCR.  Using these criteria, the number of samples analyzed was as 
follows: 20 SP NoAb – 40 samples (254 total PCR reactions); 20 SP +Ab – 40 samples (254 
total reactions); Single SP NoAb – 55 samples (272 total reactions); Single SP +Ab – 49 
samples (243 total reactions).   
 
Samples were assayed for gene expression using a two-step nested PCR procedure.  
Round 1 of PCR was conducted in 50 μL using PCR Master Mix (Promega, Madison, WI), 
and gene-specific primers A and B listed in Table 3.2.  Then 2 μL of the PCR product from 
Figure 3-1 Representative Hprt1 RT-PCR results for analysis of samples for Figure 3-3.   
Following cDNA synthesis, all 20-cell-pool and Single-cell SP samples were tested for the presence of template 
using the Hprt1 gene as an internal control.  Negative samples (Lanes 1, 5, 6, 9-11, 13) were discarded, while 
positive samples (Lanes 2-4, 8, 12, 14) were further analyzed by PCR for multiple genes of interest.  Lanes 7 
and 15 are no-template controls 
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round 1 was used as a template for a second round of PCR using gene-specific primers C and 
D listed in Table 3.2.  PCR conditions were as follows: 94°C 45”; (annealing temp., Table 
3.2) 45”; 72°C 45”; 40 cycles.  The PCR product from round 2 was then run on a gel 
containing ethidium bromide and scored as positive or negative for gene expression. 
Real Time Quantitative RT-PCR— Pools of 200-500 SP cells were sorted (based on 
Hoechst dye exclusion) into 8-well mRNA Isolation GeneStrips containing 15 μL Working 
Lysis Buffer (RNAture, Irvine, CA).  Cell lysates were allowed to hybridize to GeneStrips 
Hybridization Tubes for 90 minutes at room temperature, and then washed three times with 
wash buffer.  Based on the solution-phase synthesis protocol provided in the GeneStrips 
manual, cDNA was generated using SuperScript II Reverse Transcriptase (Invitrogen, 
Carlsbad, CA), dNTPs (Amersham Biosciences, Piscataway, NJ), and Random Hexamer 
Primers (RNAture, Irvine, CA).  The resultant cDNA was then subjected to quantitative real-
time PCR analysis using the ABI Prism 7000 sequence detection system (Applied 
Biosystems (ABI), Foster City, CA).  We used commercial TaqMan® Gene Expression 
Assays (ABI) as the gene-specific probe and primer sets for analysis of all genes studied.  
Real time PCR reactions were set up using TaqMan® Universal PCR Master Mix (ABI). 
Data was analyzed using the 2-ΔΔCT method as previously described [179].  Briefly, 
data is presented as the fold change in gene expression normalized to an internal control gene 
(Actb) and relative to a calibrator sample (untreated SP cells). 
Transplantation— Wild-type B6 female mice (CD45b) were lethally irradiated 
(9.5Gy total body irradiation from a 137Cs source) and anesthetized with tri-bromo-ethanol 
(Avertin, Sigma-Aldrich, St. Louis, MO) for retro-orbital injection of the indicated dose of 
GFP+ SP cells plus 2 x 104 whole bone marrow cells from B6-CD45a mice.  Since the 
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frequency of HSC in whole bone marrow is one in 105 cells, the B6-CD45a whole bone 
marrow cells are considered to be short term repopulating (STR) cells.  The transplanted 
animals were maintained in microisolator cages with autoclaved food and acidified (pH 2.0) 
sterile water supplemented with neomycin sulfate for the first 2 weeks after transplant. 
Analysis for Donor Cell Repopulation— At various days following transplantation, 
mice were anesthetized using tri-bromo-ethanol and approximately 100 μL of peripheral 
blood was collected from the retro-orbital sinus into 1.5 mL eppendorf tubes containing 10 
μL EDTA (25 mg/mL).  Red blood cells were lysed using ACK lysis buffer (0.15 M NH4CL, 
1.0 mM KHCO3, 0.1 mM Na2EDTA, pH 7.4).  The remaining cells were washed in PBS with 
2% FCS and then stained with PE-anti-CD45a (A20, Pharmingen, San Jose, CA).  Dual-laser 
FACS analysis was performed with a FACScan machine (Becton Dickinson).  Samples were 
gated based on high forward scatter (to avoid residual debris from ACK lysis step), and SP-
derived cells were identified based on fluorescence intensity of eGFP, while B6-CD45a-
derived cells were identified based on fluorescence intensity of PE. 
Cell Cycle Analysis— SP cells were sorted based on Hoechst dye efflux, then 
resuspended in 250 μL HBSS+ buffer with 0.1% sodium citrate and 50 μg/mL propidium 
iodide.  Cells were incubated on ice for 10 minutes then analyzed using flow cytometry (488 
nm excitation) and Modfit software (Verity Software House Inc., Topsham, ME) to 
determine the percentage of cells in each phase of the cell cycle. 
Statistical Analysis— Two-tailed Student t-tests were performed for comparisons of 
quantitative RT-PCR results.  Sigmastat software was used for statistical calculations. 
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Table 3.1 Primer sequences and PCR conditions for RT-PCR in SP compared to SKL studies 
TRANSCRIPTION FACTORS PRODUCT SIZE (bp) CONDITIONS (+) CONTROL 
Tal1 [180] 
(f) 5’-CGC GGA TCC ACG GAG CGG CCG CCG AGC GCG 570 94°(45”) 62°(45”) 72°(60”) 10% DMSO added bone marrow (r) 5’-CCG GAA TTC CGC GCC GCA CTA CTT TGG TGT G 
Gata1 (hematopoietic) [93] 
(f) 5’-ACC TGA AGG AGC TTG AAA TAG AGG C 290 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-CAT TGG CCC CTT GTG AGG CCA GAG A 
 
GROWTH FACTOR RECEPTORS - HEMATOPOIETIC PRODUCT SIZE (bp) CONDITIONS (+) CONTROL 
Kit (Stem Cell Factor) [181] 
(f) 5’-GGC TCA TAA ATG GCA TGC TC ~350 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-TAT CTC CTC GAG AAC CTT CC 
Mpl (Thrombopoietin receptor) [182] 
(f) 5’-GGC TCG AGA AGT GGC AAT TTC CTG CG ~400 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-GGC TCG AGG GGC TGC TGC CAA TAG C 
Il3ra [183] 
(f) 5’-GAA CAG ATT CCA CCA TGG CCT CCT TG 228 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-CTG TCT TCA CAG GCA TCA CCT CTG 
Epor (Erythropoietin receptor) [183] 
(f) 5’-AGG CCG CAC TGA GTG TGT TC 356 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-GGC TCC ACC ACA GAC AAC CA 
 
GROWTH FACTOR RECEPTORS – ENDOTHELIAL PRODUCT SIZE (bp) CONDITIONS (+) CONTROL 
Kdr (Flk-1, VEGF receptor) [93] 
(f) 5’-CAC CTG GCA CTC TCC ACC TTC 239 94°(45”) 55°(45”) 72°(45”) Py4.1 (endothelial) (r) 5’-GAT TTC ATC CCA CTA CCG AAA G 
Tek (Tie-2, Angiopoietin receptor) [184] 
(f) 5’-CCT TCC TAC CTG CTA 
441 94°(45”) 57°(45”) 72°(45”) Py4.1 (endothelial) (r) 5’-CCA CTA CAC CTT TCT TTA CA 
 
MARKERS OF DIFFERENTIATION – HEMATOPOIETIC PRODUCT SIZE (bp) CONDITIONS (+) CONTROL 
Csf1r (Monocyte specific/M-CSF receptor) [93] 
(f) 5’-CTG AGT CAG AAG CCC TTC GAC AAA G 
274 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-GAA ACA GCT TCC CGA AGA CTG AGT C 
 45 
Hbb-b1 (β-major, Erythroid specific) [93] 
(f) 5’-CTG ACA GAT GCT CTC TTG GG 578 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-CAC AAA CCC CAG AAA CAG ACA 
Mpo (Myeloid specific) [181] 
(f) 5’-CGC TTC TCC TTC TTC ACT GG ~320 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-CTG CCA TTG TCT TGG AAT CG 
Pecam1 (Platelet/endothelial cell adhesion, non-specific) 
(f) 5’-GTC ATG GCC ATG GTC GAG TA 260 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-CTC CTC GGC ATC TTG CTG AA 
 
CHEMOKINE RECEPTORS PRODUCT SIZE (bp) CONDITIONS (+) CONTROL 
Ccr1 (Mip-1α receptor) 
(f) 5’-TGG AGT GGT GGG CAA TGT CCT 576 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-CGC ACG GCT TTG ACC TTC TTC 
Ccr4 (Mip-1α receptor) 
(f) 5’-GCC ATC TCG GAT TTG CTG TT 464 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-TGC GCA CTG CTC TGT TCT TCT 
Ccr5 (Mip-1α receptor) 
(f) 5’-GTG AAA CAA ATT GCG GCT CAG 597 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-GCG AAA CAG GGT GTG GAG AA 
Cxcr4 (Stromal derived factor-1 receptor) 
(f) 5’-TTG TCC ACG CCA CCA ACA G 521 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-CCC GAG GAA CCG ATA GAG GAT 
 
OTHER MARKERS OF HSC PRODUCT SIZE (bp) CONDITIONS (+) CONTROL 
Cd34 (Stem cell activation marker) [181] 
(f) 5’-TTG ACT TCT GCA ACC ACG GA ~300 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-TAG ATG GCA GGC TGG ACT TC 
Fancc (Fanconi Anemia group C protein – HSC maintenance) 
(f) 5’-AAA GAC AGA GGA GAC GCC AC 463 94°(45”) 58°(45”) 72°(60”) bone marrow (r) 5’-AAG AGC AAC ACA AAT GGT AAG G 
 
HOUSEKEEPING PRODUCT SIZE (bp) CONDITIONS (+) CONTROL 
Hprt1 (Hypoxanthine phosphoribosyl transferase) [184] 
(f) 5’-CAC AGG ACT AGA ACA ACC TGC 248 94°(45”) 55°(45”) 72°(45”) bone marrow (r) 5’-GCT GGT GAA AAG GAC CTC T 
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Table 3.2 Primer sequences and PCR conditions for RT-PCR in SP (+SKL Ab) compared to SP (Untreated) studies.   
SP cell samples were assayed for gene expression using a two-step nested PCR procedure.  Primers A and B (outer) were used for the first round of PCR; then 
the PCR product from round 1 was used as a template for a second round of PCR using primers C and D (inner). 
 
GENE PRIMER A PRIMER B PRIMER C PRIMER D ANNEAL 
TEMP 
Tal1 AGCGCTGCTCTATAGCCTTA CCTTCCTCCTCCTGGTCATT ACTAGGCAGTGGGTTCTTTG TGAGTAACTTGGCCAGGAAA 62 
Gata1 CCAAGAAGCGAATGATTGTC TCAAGGCTATTCTGTGTACC CCCAATGCACTAACTGTCAA AAAGGCATAAGATGGCTGAC 60 
Runx1 GAAGAACCAGGTAGCGAGAT TGGATCCCAGGTACTGGTAG TTCAACGACCTCAGGTTTGT ACTGGTAGGACTGGTCATAG 60 
Tgif CCAAGGAGTCAGTCCAGATT AGAAAGGCCCATCCTTCAAT ACTGGCTGTATGAACACAGA GTCACAGTGGTATGGCAGAT 60 
Kit GATGCCAGTGCTTCCGTGAC TCCCGAAGGCACCAGCTCCC ACAGGAGCAGAGCAAAGGTG CGACCACAAAGCCAATGAGC 62 
Cd34 TTGACTTCTGCTACCACGGA TAGATGGCAGGCTGGACTTC ATCCCCATCAGTTCCTACCA GTAGGCAGTATGCCAGTTGG 60 
Ly6a  
(Sca-1) CTCAGGGACTGGAGTGTTAC CTCCATTGGGAACTGCTACA GGAGTGTTACCAGTGCTATG TGCTACATTGCAGAGGTCTT 60 
Il3ra CTCAGAGCCACAGGAATACA TAGCCACTGAAGTCACCAAG GCCACAGGAATACAATGTCT AAGTCACCAAGGCTGTCTTC 62 
Tek  
(Tie-2) GGAGATGTGAAGCTCAGAAG CTGCCTTCTTTCTCACACTG TAGCCGTCCTTGTACTACTT TCCTTGGAACCGATCACATA 60 
Epor CACCTATGACCACCCACATC GCGAGATGAGGACCAGAATG ACCACCCACATCCGATATGA GACAGCGTCAAGATGAGAGG 60 
Csf1r CACAGATAAAATTGGAGCCTA TGGAAGTTCATGGTGGCCG CAAGCTGGTGCGGATTCGAG TGCCAGCGTCTTGGAAGTCC 56 
Mpo CAATGACCCTCGAATCAAGA AAGCATTGGTGAAGACATTG CCAGGAACAACATCACCATT GTACTGCGGTAGGTACTTCT 60 
Pecam1 AGCAGTGAAGCTGTCTACTC GGGTGGGAATGGCAATTATC ACTACACCTGCAAAGTGGAA ATGTCTCTGGTGGGCTTATC 62 
Ccr1 TGGAGTGGTGGGCAATGTCC CGCACGGCTTTGACCTTCTT GCTCATGCAGCATAGGAGGC GGGGAAATGAGGGCTACAGG 62 
Cxcr4 AACCCTGCTTCCGGGATG GCTGATGAAGGCCAGGATGA CCTGCTTCCGGGATGAAA ATGAAGGCCAGGATGAAC 60 
Tert AATACGGCAAGCTATCACTG CTTGAGACGCTGGGTGAAAT ATCACTGCAGGAACTGATGT AGCTCTGGTACCCATGCTAT 60 
Abcg2 GAACATCGGCCTTCAAAGAG CATGGAACTGGCCGTATAAG GCCTTCAAAGAGCCAGTCTA CATCCACCGTCTTCTTCAGT 60 
Hprt1 AGCTTTACTAGGCAGATGGC GCAGTACAGCCCCAAAATGG CGAAGTGTTGGATACAGGC ACATCAACAGGACTCCTCG 60 
Itga2b AGCTGCATCTAAAGGCAGAG CAGCTCCAACACATTGTCAG CTGCAGCTGGACTTACAGAA ATTGTCAGCACCGATTAGGA 60 
 47 
D. RESULTS 
Stem cell-related gene expression is altered in SP cells compared to SKL cells— In 
order to compare gene expression in two defined cell populations that are highly enriched for 
hematopoietic stem cell activity, RT-PCR analyses were performed with sorted samples of 
SP and SKL cells.  Due to the rarity of these cell populations in bone marrow, we chose to 
examine the expression of select genes individually rather than in an array format.  
Considerable amplification of transcripts would be required to generate enough starting 
material for analysis by array, which can introduce significant bias due to variable 
amplification efficiency.  Thus we studied the expression of 18 separate genes.  Detection of 
a housekeeping gene, hypoxanthine phosphoribosyltransferase (Hprt1), was used as a 
positive control for each sample, so samples scoring negative for Hprt1 were not included in 
the analysis.  We analyzed a total of 231 PCR results from 48 SKL sorted samples and 224 
PCR results from 46 SP sorted samples (each sample represents a pool of 20 cells).  Each 
sample was scored as positive or negative for gene expression, and overall gene expression 
frequency was defined as the percentage of positive samples in all samples analyzed. 
For this analysis, we focused on genes relevant to hematopoietic cell physiology, 
which can be organized into the following basic categories: transcription factors (Tal1, 
Gata1) [185], growth factor receptors (hematopoietic [38]: c-Kit [186], Csf1r, Mpl, Epor, 
Il3ra; vascular: Kdr (Flk-1) [187], Tek (Tie-2) [188]), markers of differentiation (Pecam1 
[189], Csf1r [190], Mpo [191], Hbb-b1 [192]), chemokine receptors related to stem cell 
homing (Cxcr4 [193]) or cycling (Ccr5, Ccr4, Ccr1) [194], and other markers of HSC 
activation (Cd34 [195], Fancc [196]).  Overall, the frequency of gene expression was lower 
in SP cells compared to SKL cells for all categories, with the exception of the chemokine 
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receptor category, which showed the opposite trend (Table 3.3).  Within the chemokine 
receptor category, we observed similar expression frequency of Cxcr4 in both cell 
populations, which is not surprising since this receptor has been shown to be required for 
homing of transplanted cells to the bone marrow [197].  In contrast, our data demonstrate a 
higher frequency of expression of the MIP-1α (Ccl3) receptors Ccr1, Ccr4 and Ccr5 in SP 
cells.  From these results we made the general observation that the SP population and the 
SKL population clearly have different gene expression profiles with respect to genes 
important to hematopoietic stem cell physiology, but could not conclude a causal effect of 
antibody binding in inducing such gene expression differences. 
Table 3.3 Differences in frequencya of gene expression in SKL compared to SP cells. 
Genes more frequently 
expressed in SP Cells 
Genes expressed with 
similarb frequency in SP 
and SKL cells 
Genes more frequently 
expressed in SKL cells 
Ccr5 
Ccr4 
Ccr1 
Cxcr4 
Tek (Tie-2) 
Kdr (Flk-1) 
Mpl 
Tal1 
Hbb-b1 
Pecam1 
Csf1r 
Mpo 
Epor 
Il3ra 
Kit 
Gata1 
Cd34 
Fancc 
aEach PCR sample (representing a pool of 20 cells) was scored as positive or negative for gene expression.  
Frequency is defined as the percentage of positive samples among all samples analyzed. 
bGene expression frequencies were scored as similar if the difference in percent positive samples was less than 
15%. 
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The SKL antibody cocktail reduces the frequency of expression of stem cell-related 
genes in SP cells— The SP and SKL isolation protocols differ fundamentally in that the SKL 
protocol involves the use of antibodies that bind to cell surface molecules.  We therefore 
hypothesized that the presence of these antibodies may actually give rise to some of the gene 
expression differences observed between the two HSC populations.  However, the use of 
antibodies is not the only difference between SP and SKL isolation protocols, so any 
phenotypic differences seen by direct comparison of the two populations may not be solely 
due to the presence of the SKL antibody cocktail.  Thus, in all subsequent studies, we 
compare untreated cells sorted based on Hoechst dye exclusion (SP untreated) to the same 
population of cells that were incubated with the SKL antibody cocktail prior to sorting based 
on Hoechst dye exclusion (SP + SKL Ab).  Figure 3-2 illustrates the sorting gate used to 
isolate SP cells from whole bone marrow, and the right-hand panel shows a representative 
check of post-sort purity.   
 
Figure 3-2 Sorting gate for Side Population (SP) cells based on Hoechst dye exclusion.   
Whole bone marrow cells were incubated with 5 μg/mL Hoechst 33342.  Flow cytometric emission monitoring 
at both 405 nm and 670 nm allows for selection of the Side Population of cells (gated, left panel), which 
exclude the Hoechst dye.  The right panel demonstrates a post-sort assessment of purity.   
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To determine whether the presence of the SKL antibody cocktail alters gene 
expression within the SP population, we conducted RT-PCR analyses for hematopoietic cell-
related genes on untreated SP cells and SKL antibody-treated SP cells.  We studied the 
expression of nineteen different genes, which can be organized into the following general 
categories: transcription factors (Tal1, Gata1, Runx1, Tgif) [185, 198-200], growth factor 
receptors (Kit, Il3ra, Tek, Epor, Csf1r) [38, 186, 188], markers of differentiation (Mpo, 
Pecam1, Csf1r) [189-191], homing molecules (Cxcr4, Itga2b) [193, 201], molecules 
involved in cycling/self-renewal (Ccr1, Tert) [194, 202], and molecules implicated in stem 
cell phenotype and/or function (Cd34, Ly6a (Sca-1), Abcg2) [13, 203, 204].  Detection of a 
housekeeping gene, Hprt1, was used as a positive control for each sample, so samples 
scoring negative for Hprt1 were not included in the analysis.  Samples were scored as 
positive or negative for gene expression, then expressed as the percentage of positive samples 
among all samples analyzed (frequency).  At least eight and as many as 22 RT-PCR samples 
were analyzed for each gene.  We first analyzed the expression of these genes in cDNA 
samples collected from twenty-cell pools of sorted cells.  Interestingly, we saw large 
differences in the frequency of expression of many of the genes studied between untreated SP 
cells and SP cells that had been treated with the SKL antibody cocktail (Figure 3-3 A).  The 
antibody treated samples were generally less likely to express key HSC-related transcription 
factors Tal1, Gata1, and Runx1 as compared to untreated samples.  At the same time, 
antibody treated samples showed altered expression frequencies of Epor, Csf1r, Mpo, and 
Pecam1, which are markers of differentiated endothelial or hematopoietic cells.  Moreover, 
the MIP-1α (Ccl3) receptor Ccr1, which may be important in maintaining quiescence in 
HSC, was less frequently expressed in the antibody-treated SP samples.  In contrast, 
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expression of the integrin Itga2b and the SDF-1 (Cxcl12) receptor Cxcr4, which are both key 
molecules in HSC homing, was more frequent in the antibody treated samples than in 
untreated samples.   
There were several genes in the study that were expressed with very high frequency 
in both treated and untreated twenty-cell pooled samples, therefore we analyzed gene 
expression at the single cell level to further elucidate any additional differences in expression 
frequency between untreated and antibody-treated SP cells (Figure 3-3 B).  In these single-
cell samples, we noted a considerable decrease in the frequency of expression of the HSC 
markers Kit and Ly6a (Sca-1) in the antibody-treated samples.   Single-cell analysis also 
revealed an increase in Abcg2 expression frequency in antibody-treated SP cells.  Overall, 
these findings indicate that the presence of the SKL antibody cocktail results in distinct 
heterogeneity in expression of many genes important to hematopoietic stem cells and their 
progeny in the SP population.  However, the net result of this gene expression heterogeneity 
is inconclusive as it is based on expression frequency alone.  Thus, we used these results to 
direct both quantitative gene expression analyses and in vivo analysis of mice transplanted 
with antibody-treated versus untreated SP cells.   
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Figure 3-3 Frequency of gene expression in untreated and SKL antibody-treated SP cells.   
RT-PCR analysis of cDNA samples from twenty cell pools (A) or single cells (B).  Each sample was scored as 
positive or negative for expression of the indicated genes.  Results are displayed as the percentage of positive 
results in all samples analyzed.  The total number of samples analyzed for each gene and condition ranged from 
8 to 22.  The presence of the antibody cocktail results in distinct heterogeneity in expression of many HSC-
relevant genes within the SP population. (n/d=analysis not done). 
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Quantitative studies confirm that reduced gene expression is specific to SKL antibody 
cocktail— To further confirm and quantitate the gene expression differences observed, we 
next conducted quantitative RT-PCR analyses on some of the key genes that were altered 
upon antibody treatment of the SP cells.  As an additional control, we tested samples that 
were treated with the isotype controls of the SKL antibody cocktail to determine if any 
observed changes were specific to the SKL antibodies or simply a non-specific consequence 
of having antibodies in solution with the cells.  It is notable that in these studies the 
approximate time from exposure to the antibodies until analysis of gene expression was a 
minimum of four hours, thereby allowing significant time for some alteration in gene 
expression if induced by antibody exposure.  We found significant reductions in mRNA 
levels of Kit, Cd34, Tal1, and Slamf1 from untreated SP samples to SKL antibody-treated SP 
samples (p<0.05 in all cases, Figure 3-4).  Importantly, these significant reductions in 
message level were not seen in samples treated with isotype control antibodies, except in the 
case of Cd34.  Yet, despite the small but significant (p<0.05) reduction in Cd34 expression in 
the presence of isotype control antibodies, the SKL antibody-treated sample demonstrated a 
significant reduction in message level beyond the level in isotype-treated samples (p<0.03).  
Thus, the substantially decreased expression of genes critical to HSC physiology is specific 
to the SKL antibody cocktail and not a generalized antibody effect.  Furthermore, we noted a 
large (greater than 2-fold) increase in p21 (Cdkn1a) transcript levels from untreated SP 
samples to SKL antibody-treated samples, which did not occur in isotype-treated samples 
(Figure 3-4).  This result suggests a change in cell cycle status of the antibody-treated cells.  
Lastly, our results indicated no significant changes in transcript levels of several molecules 
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involved in hematopoietic cell homing and engraftment following treatment with the SKL 
antibody cocktail (Figure 3-4).   
 
Figure 3-4 Quantitative gene expression in SP cells with or without antibody treatment.   
QPCR analyses from pools of 200-500 cells are shown as the level of gene expression in the antibody-treated 
samples relative to the level of expression in the untreated samples.  The numbers in parentheses indicate the 
number of individual cell sorts analyzed.  The SKL antibody cocktail caused marked downregulation of several 
genes known to be important to hematopoietic stem cell physiology, which did not occur in isotype antibody-
treated samples. 
 
SKL antibody-treated SP cells show reduced engraftment of lethally irradiated 
recipients as compared to untreated SP cells— Given the nature of the genes whose 
expression was altered in the SKL antibody cocktail-treated SP cells, we hypothesized that 
the antibody-treated cells may have altered functional ability to repopulate the hematopoietic 
system in lethally irradiated recipients as compared to untreated SP cells.  We sorted 
untreated or SKL antibody-treated SP cells from the BM of eGFP-transgenic mice, so that we 
could follow engraftment of the SP cells using GFP fluorescence.  Transplant recipients 
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(CD45b genotype) were lethally irradiated, and then given a mixture of BM cells containing 
10, 20, or 50 SP cells (CD45b genotype, GFP+) and 2x104 whole bone marrow cells (CD45a 
genotype) via retro-orbital injection (Figure 3-5 A).  Following transplantation, peripheral 
blood was collected from recipient animals and analyzed by flow approximately once per 
month to monitor the percentage of eGFP+ (SP-derived) cells as a measure of engraftment 
and hematopoietic repopulation by the transplanted cells (Figure 3-5 B).   
 
Figure 3-5 Transplantation and engraftment analysis for untreated versus SKL antibody-treated SP cells.   
A) Lethally irradiated recipient animals (CD45b genotype) received small numbers of untreated or antibody-
treated GFP+ SP cells and 2x10e4 CD45a unfractionated bone marrow cells.   
B) Each month post-transplant, peripheral blood cells were harvested and analyzed by flow cytometry to 
determine their origin (SP donor, STR donor, or endogenous). 
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In mice receiving 20 SP cells, over the period of several months we noted that the 
percentage of SP (eGFP+) engraftment was significantly lower in the animals that received 
SKL antibody-treated SP cells than in the animals that received untreated SP cells (Figure 3-
6 A).  In particular, many mice receiving antibody-treated cells died during the fourth month 
post-transplant, which suggests that a number of SP derived cells in those mice functioned as 
short-term progenitors and there were not enough long-term stem cells to keep the mice 
alive.  Furthermore, the mice that survived past the fourth month showed very few SP-
derived cells in their peripheral blood, suggesting either deficient engraftment or a possible 
loss of long-term repopulating potential after SP cell exposure to the SKL antibodies.  Panel 
(B) of Figure 3-6 summarizes the engraftment of SP-derived cells in mice receiving all doses 
of SP cells.  Once again, many of the mice died at around four months post-transplant when 
the short-term progenitor cells were exhausted, and the SP cell engraftment is significantly 
lower in surviving mice that received SKL antibody-treated SP cells.  These findings indicate 
that a functional consequence of SKL antibody binding to SP cells is to significantly reduce 
their ability to stably engraft lethally irradiated mice, particularly when transplanting small 
numbers of cells. 
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Figure 3-6 Engraftment of transplanted SP cells.   
Flow cytometric analysis determined the percentage of recipient peripheral blood derived from the transplanted 
SP cells (GFP+).  (A) Values are shown as the mean ± SEM of the percentage of GFP+ cells in all living mice at 
each timepoint (indicated by numbers in parentheses).  The graph represents the average of two separate 
transplants in which the mice received a dose of 20 SP cells (+/- SKL Ab). Panel (B) summarizes all transplants 
performed, using multiple different doses of SP cells.  Values are shown as the mean ± SEM of the percentage 
of GFP+ cells as a function of the starting dose of SP cells. Beginning around four months post-transplant, the 
mice receiving SKL antibody-treated SP cells showed significantly reduced levels of SP-derived cells in their 
peripheral blood as compared to the mice receiving untreated SP cells. 
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The SKL antibody cocktail markedly increased the numbers of cycling SP cells— In 
order to explore a possible mechanism for the observed effects of the SKL antibody cocktail 
on the phenotype of SP cells, we conducted cell cycle analysis of the SP population with or 
without SKL antibody treatment.  Untreated SP cells are usually a quiescent population, with 
over 90% of cells in G0/G1, approximately 8% of cells in S-phase, and 2% of cells in G2/M 
(Figure 3-7 A).  When these cells were exposed to the SKL antibody cocktail prior to 
Hoechst sorting, the percentage of cells in S-phase more than doubled to almost 20%, with a 
marked reduction of cells in G0/G1 (Figure 3-7 B).  Importantly, when the cells were treated 
with isotype control antibodies prior to sorting, the cell cycle profile of isotype-treated cells 
was very similar to that of untreated cells (2% increase in S-G2M).  These findings suggest 
that the SKL antibody cocktail induces cells within the SP population to enter the cell cycle, 
which may in part explain the changes in gene expression profile and stem cell functionality 
seen between untreated SP cells and SKL antibody-treated SP cells. 
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Figure 3-7 Cell cycle analysis of SP cells with or without antibody treatment.   
A) Representative flow cytometric histograms showing the DNA content of SP-sorted cells with or without 
prior antibody treatment.  Percentage numbers indicate the portion of the cell population in the designated phase 
of the cell cycle as determined by Modfit software.   
B) Summary of cell cycle phase distribution of SP cells following the indicated antibody treatments.  Note the 
large increase in S phase cells caused by the SKL antibody cocktail.  Graphs represent the average of three 
separate experiments. 
E. DISCUSSION 
The two major determinants of successful hematopoietic stem cell transplantation are 
1) repopulation of all components of the hematolymphoid system via multipotent 
differentiation of the stem cells; and 2) long-term maintenance of all cell types via self-
renewal of the stem cells.  Many different protocols have been established to isolate or enrich 
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the stem cells for transplants, and in all cases, the desired cell population comprises a small 
fraction of the original cell source.  In addition, available stem cell numbers may be reduced 
depending on the source of the cells (i.e. umbilical cord blood) or by manipulation prior to 
transplantation (i.e. gene therapy).  Therefore, it is important to understand the impact a 
chosen enrichment protocol will have on HSC function in order to maximize transplant 
efficiency. 
We describe here the negative impact of certain antibodies to cell surface proteins on 
the long-term repopulating ability of HSC from the SP fraction of murine whole bone 
marrow.  Our initial gene expression profile analysis comparing SKL-sorted cells to SP-
sorted cells revealed many differences in the frequency of expression (percentage of samples 
positive for expression) of many genes related to HSC activation, homing, cycling, growth 
factor responsiveness, differentiation, and gene transcription.  Overall, the SP population was 
less transcriptionally active with respect to HSC-related genes and showed less evidence of 
differentiated cells.  The only genes studied which showed a significantly higher frequency 
of expression in SP cells were the chemokine receptors Ccr1, Ccr4 and Ccr5, which bind to 
the common ligand MIP-1α (Ccl3).  In several reports, MIP-1α has been shown to be a 
negative regulator of proliferation of hematopoietic stem cells [205-207].  The increased 
frequency of MIP-1α receptor expression in SP cells suggests that MIP-1α may play a 
substantial role in maintaining quiescence within the SP population.  Furthermore, MIP-1α 
binding to CCR5 has been shown to inhibit chemotaxis through desensitization of CXCR4-
mediated homing to SDF-1 (CXCL12) in bone marrow B cell progenitors [208].  Thus, the 
higher frequency of expression of proliferation- and migration-inhibitory chemokine 
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receptors coupled with lower frequency of expression of growth factor receptors and markers 
of differentiation suggest a more quiescent phenotype of SP cells compared to SKL cells.   
The fundamental difference between SKL sorting and SP sorting of HSC is the use of 
antibodies to cell surface proteins.  We hypothesized that antibodies within the SKL sorting 
cocktail are a cause of transcriptional changes in HSC which may lead to altered function.  In 
order to directly test this hypothesis, we compared the effects of SKL antibody exposure 
versus no antibody exposure on a single HSC population (SP cells).  We again found 
significant differences in the expression of a number of stem cell relevant genes that was not 
seen after exposure to irrelevant isotype control antibodies, suggesting some loss of the stem 
cell phenotype.  Furthermore, through in vivo transplantation studies using small numbers of 
stem cells we show that exposure to the SKL antibody cocktail resulted in a significant loss 
of long-term repopulating potential of SP HSC.   
Two general mechanisms that could explain the defect we saw in SKL antibody-
treated SP cell long-term repopulating capability are: 1) a localization defect (including 
homing, migration, and engraftment in the niche); or 2) an alteration in intrinsic stem cell 
properties, i.e. multipotentiality and self-renewal.  Our quantitative PCR results demonstrate 
that, at least at the transcriptional level, the SKL antibodies do not alter the expression of any 
known molecules important to HSC homing or migration.  Therefore, a localization defect is 
unlikely to explain the reduced long-term repopulation shown by SKL-treated SP cells.   
Our results support the idea of an intrinsic loss of stem cell properties caused by 
antibody exposure as demonstrated by significant changes in cell surface marker phenotype 
and cell cycle profile.  Expression levels of Kit, Slamf1, and Cd34 were significantly down-
regulated in response to SKL antibody exposure, suggesting a possible loss of both long-term 
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and short-term repopulating HSC [18, 195, 209].  Cell cycle analysis showed that SKL 
antibody exposure resulted in a two- to three-fold increase in S-G2M phase cells that again 
was not seen with isotype control antibody exposure.  Hematopoietic stem cells in S/G2 
demonstrate a shift in gene expression marked by down-regulation of transcription regulators 
and protein synthesis factors with concomitant up-regulation of cell cycle and chromatin 
remodeling genes [176].  Importantly, this shift is associated with a significant reduction in 
HSC engraftment [176, 210, 211].  In addition, several studies have shown detrimental 
effects of induced proliferation on HSC due to loss of developmental potential and/or self-
renewal [21, 22].   
Quantitative RT-PCR analysis revealed a significant up-regulation of p21 (Cdkn1a) 
expression upon SKL antibody exposure.  While p21 in HSC is most often described by its 
role in maintaining quiescence by the inhibition of cell cycling [212], this protein has also 
been implicated in some cases as a promoter of cell cycling through its role as an adaptor or 
scaffold protein [213, 214].  In fact, growth factor treatments which signal through mitogen-
activated protein kinase pathways have been shown to induce transcriptional activation of 
p21 via a p53-independent pathway [215, 216].  Furthermore, in a human myeloid cell line, 
increasing levels of p21 displaced p27 from cyclin-dependent kinase 2, leading to enhanced 
cell proliferation when stimulated by kit ligand [217].  These studies are in accordance with 
our findings showing increased p21 gene expression and increased cell cycling by exposing 
SP cells to the SKL antibody cocktail. 
The potential impact of our findings on the possible detrimental effects of antibody-
based enrichment strategies may be relevant to stem cell isolation in non-hematopoietic 
tissue types as well.  Cell surface antigens useful for stem or progenitor cell isolation have 
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been identified in several other tissue types, including neural cells [218-220], stromal cells 
[221], endothelial cells [222, 223], skeletal muscle [224] and liver [225, 226].  Given that 
cells with the SP phenotype have also been identified in brain, skeletal muscle and liver 
[227], our results suggest that SP-based stem cell isolation may also have similar advantages 
over antibody-based enrichment in tissues other than bone marrow. 
Chapter 4 SIDE POPULATION SORTING OF HEMATOPOIETIC STEM CELLS 
FROM tEpoR-TARGETED EMBRYONIC STEM CELLS 
A. ABSTRACT 
We have generated transgenic murine embryonic stem cell (ESC) lines expressing 
GFP in addition to a truncated erythropoietin receptor (GNtEpoR) with the goal of deriving 
hematopoietic stem cells (HSC) that may be fluorescently tracked in vivo and expanded with 
exogenous erythropoietin (Epo) administration.  In this report, we describe the application of 
dye efflux-based sorting on day 3 embryoid bodies (EB) to identify a Side Population (SP), 
which we hypothesized would contain ESC-derived hematopoietic stem cells (HSC).  Using 
a conditioned NOD.scid newborn mouse transplant model, we demonstrate long-term 
multilineage hematopoietic repopulation by ESC-derived cells.  Furthermore, activation of 
the tEpoR transgene in these cells by exogenous administration of Epo improved the 
efficiency of transplantation, suggesting a role for this transgene in the expansion of ESC-
derived hematopoietic progenitors.  Lastly, we have conducted a focused stem cell 
microarray analysis on the SP-sorted day 3 EB cells grown in the presence or absence of 
Epo.  The results of this analysis will be useful in characterizing the phenotype of ESC-
derived HSC, and will clarify the relationship of these cells to HSC derived from classical 
embryonic- or adult-derived HSC. 
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B. INTRODUCTION 
Despite more than two decades of study on hematopoietic differentiation from 
embryonic stem cells (ESC), the potential to generate therapeutic hematopoietic stem cell 
populations (HSC) from ESC has not yet been realized [77, 228].  Based on results from the 
small number of publications reporting engraftment of ESC-derived hematopoietic cells, it 
has proven exceptionally difficult to demonstrate engraftment under “normal” circumstances 
(i.e., without potentially variable long term culture conditions or enforced expression of 
oncogenes or transcription factors) [120, 228], (See also Table 1.2).  There have been three 
published reports of phenotypic selection of cell populations for transplantation based on the 
expression of specific cell surface molecules [108, 113, 115].  While these groups report 
modest to high levels of donor cell engraftment (15-100%), molecular studies of 
hematopoietic development in the ESC system indicate that the cell surface phenotype of 
HSC from embryonic sources may differ significantly from that of HSC from adult sources 
[86, 87, 89]; thus it is difficult to predict which marker molecules will be useful in the 
enrichment of transplantable populations [77, 109].  Furthermore, we have previously 
reported that antibodies to common HSC surface marker antigens can limit engraftment of 
HSC from bone marrow, so it is feasible that the same may be true for embryonic HSC 
([229], see also Chapter 3 of this dissertation).   
An alternative to antibody-based selection of HSC is the isolation of cells with the 
capacity to efflux the fluorescent DNA-binding dye Hoechst 33342, known as the Side 
Population, or SP [3, 227].  SP sorting was first characterized as a way to isolate long term 
repopulating HSC from murine bone marrow [3], and has subsequently demonstrated utility 
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in the enrichment of stem or progenitor populations from several other adult tissues 
(reviewed in [227]).  Moreover, an SP has been identified in undifferentiated ESC, in which 
dye efflux capacity is highly correlated with the percentage of chimerism achieved by the 
cells in blastocyst reconstitution experiments [230].  These findings suggest that the 
association between SP phenotype and stem cell function may endure in embryonic as well 
as adult-derived tissues. 
Beyond the issue of HSC phenotype in the ESC model system is the recurrent theme 
that the adult bone marrow environment may not be suitable for proper homing or support of 
an HSC derived from an embryonic source [109, 120].  Likewise, a clear difference has been 
demonstrated between the engraftment abilities of embryo-derived yolk sac (YS) HSC versus 
adult-derived bone marrow (BM) HSC; namely that YS cells cannot engraft irradiated adult 
recipients unless they are exposed to specific environmental cues such as those provided by 
the neonatal liver [70] or aorta-gonad-mesonephros-derived stromal tissue [69].  
Hematopoietic development within embryoid bodies (EB) kinetically and phenotypically 
mirrors that of hematopoiesis in the developing yolk sac [79, 88], thus it follows that 
requirements for engraftment may be similar between ESC-derived HSC and YS cells [231]. 
The current work describes the isolation of hematopoietic stem and progenitor 
populations from EB-based differentiation cultures of ESC.  We demonstrate long-term 
multilineage engraftment of SP-sorted cells from day 3 EBs as well as unsorted cells from 
blasts-colony forming cell (BL-CFC) cultures, as defined by Keller et al [82, 83].  In both 
cases, engraftment was achieved through injection of the cells into in utero conditioned 
newborn mouse recipients.  Furthermore, we provide evidence that ligand-dependent 
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activation of a truncated erythropoietin receptor (tEpoR) transgene can enhance the 
efficiency of engraftment of ESC-derived HSC.   
C. MATERIALS AND METHODS 
Transgene Constructs and Gene Targeting— Both transgenic constructs created for 
this study contained the humanized Renilla reniformis green fluorescent protein with nuclear 
localization signal (hrGN, Stratagene) to serve as a fluorescent cell marker.  The GNtEpoR 
construct also included the coding sequence for an erythropoietin receptor with a carboxy-
terminal, 91-amino acid truncation, which has been previously described [45, 46].  All 
transgenes were expressed from a 1.3-kb genomic fragment containing the human β-actin 
promoter [232].  The transgene constructs were cloned into a modified version of the previously 
described Hprt targeting vector pSKB1 [138].  Targeting constructs were linearized with PmeI 
prior to electroporation.  Cell culture, electroporation and selection of ESC were carried out 
using the method described by Bronson et al. [138].  The ESC line used in these studies is a 
subclone of E14TG2a, a cell line derived from 129/Ola mice with an ~50kb deletion in its Hprt 
gene [139] (Fig. 4-1).  Following gene targeting, Southern blot analysis was performed on 
BamHI-digested genomic DNA from ESC clones using a random primer-labeled RsaI probe 
from intron 3 of the mouse Hprt gene.  Expression of the tEpoR transgene was also 
confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) using the following 
primer set: forward, CGCTGTTGCTGACGGTTCTGG; reverse, CTGAGAGGTTCTCACTGCATGG. 
In Vitro Differentiation— Undifferentiated ESC culture conditions and EB formation 
were previously described in Chapter 2 of this dissertation.  Hemangioblast colonies, 
primitive and definitive erythroid, and myeloid colonies were generated as described by 
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Keller et al [83].  Briefly, for hemangioblast colony formation, day 3 EB cells were 
disaggregated with 0.05% Trypsin / 0.02% EDTA (Gibco) and plated at 50,000 cells/mL in 
IMDM with 1% methylcellulose, 10% Hematopoietic Differentiation Fetal Bovine Serum 
(Stem Cell Technologies), 25% D4T cell conditioned media [92], and 5 ng/mL vascular 
endothelial growth factor (VEGF, R&D Systems).  For formation of primitive and early 
definitive erythroid and myeloid colonies, day 6 EB cells were plated at 50,000 cells/mL in 
IMDM with 1% methylcellulose, 15% plasma-derived serum (Animal Technologies), 20 
U/mL erythropoietin (Amgen), c-kit ligand (1% conditioned medium), thrombopoietin (2% 
conditioned medium), 5% protein-free hybridoma medium (Gibco), interleukin-3 (1% 
conditioned medium) and 5 ng/mL interleukin-11 (R&D Systems). 
SP Isolation from day 3 EBs— Day 3 EB cells were disaggregated with 0.05% 
Trypsin / 0.02% EDTA (Gibco), then suspended at 106 cells/mL in prewarmed (37˚C) RPMI 
medium (Gibco) containing 2% fetal bovine serum, 10 mM HEPES, 100 U/mL penicillin, 
100 µg/mL streptomycin and 5 µg/mL Hoechst 33342.  Cell suspensions were incubated at 
37˚C for 90 minutes with agitation every 15 minutes.  After the incubation period, cells were 
immediately centrifuged at 300g for 10 minutes at 4˚C.  Cell pellets were resuspended in 2 
mL ice-cold HBSS with 2% fetal bovine serum, 10 mM HEPES, 100 U/mL penicillin, 100 
µg/mL streptomycin and 2 µg/mL propidium iodide.  For SP inhibitor studies, Hoechst dye 
incubation was carried out in the presence of 50 µM verapamil (Sigma) or 5 µM reserpine 
(Sigma).  FACS sorting of side population cells was performed as described in Chapter 3 of 
this dissertation.  A representative example of the SP sorting gate and post-sort purity are 
shown in Figure 4-3.  For analysis of the cell surface phenotype of EB-SP cells, prior to SP 
sorting the cells were stained with a phycoerythrin (PE)-Cy5.5-conjugated anti-mouse 
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CD117 antibody (anti-c-KIT, clone 2B8, eBioscience) and an allophycocyanin (APC)-
conjugated anti mouse Ly-6A/E antibody (anti-SCA-1, clone E13-161.7, BioLegend).  
Lineage-depleted bone marrow cells were prepared as a reference sample by using the 
Miltenyi Biotec Lineage Cell Depletion Kit according to package insert instructions.   
Animals and transplantation of ESC-derived cells— Transplant experiments were 
conducted in NOD.scid mice (a generous gift from Dr. R. Tisch, UNC) using the neonatal 
transplant model described by Johnson and Yoder [233].  Briefly, timed matings were set up 
and on the morning of days E18 and E19, pregnant dams were given intraperitoneal 
injections of 15.5 mg/kg of busulfan (IVBusulfex, BioPharma).  Within 24 hours of birth, 
recipient pups were injected via the facial vein with 2.5-20 x 103 EB-SP cells or 50-150 x 103 
HB culture cells.  Mice were housed in sterile microisolator cages with autoclaved food 
according to a protocol approved by the UNC Institutional Animal Care and Use Committee.   
Flow Cytometric Analysis of Peripheral Blood of Recipient Mice— Approximately 
every four weeks for up to 18 weeks following transplantation, recipient mice were bled via 
the facial vein and peripheral blood was assayed for evidence of ESC-derived hematopoietic 
engraftment as measured by GFP fluorescence or expression of the MHC class I isotype 
H2Kb (using an R-phycoerythrin (PE)-conjugated anti-mouse H2Kb antibody, clone AF6-
88.5, BD Pharmingen).  After antibody staining but prior to flow cytometric analysis on a 
CyAn cytometer (Dako Cytomation), red blood cells were lysed using FACSLyse (Becton 
Dickinson).  Residual red cell debris was eliminated from flow analysis by gating on cells 
expressing the pan-hematopoietic cell surface marker CD45 (using a peridinin chlorophyll-a 
protein (PerCP)-conjugated anti-mouse CD45 antibody, clone 30-F11, BD Pharmingen).  To 
determine multilineage engraftment, peripheral blood cells were also stained with the 
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myeloid specific marker Gr-1 (PE-Cy7-conjugated anti mouse Ly-6G and Ly-6C, clone RB6-
8C5, BD Pharmingen) as well as the lymphoid specific markers CD3 (T cells) and B220 (B 
cells) (APC-conjugated anti-mouse CD3ε, clone 145-2C11, eBioscience, and APC-
conjugated anti-mouse CD45R/B220, clone RA3-6B2, BD Pharmingen).  To reduce any non-
specific antibody labeling, peripheral blood cells were incubated with anti-mouse 
CD16/CD32 (clone 2.4G2, BD Pharmingen) for five minutes prior to antibody staining.   
Microarray Analysis of EB-SP cells, YS cells and Lin- BM cells— EB-SP cells and 
Lin- BM cells were prepared as previously described in this chapter.  Yolk sac cells were 
dissected from day 9.5 embryos of C57BL/6J mice (The Jackson Laboratory) and 
disaggregated using Liberase Blendzyme-3 (Roche) as described by Johnson and Yoder 
[233].  Prepared cell samples were suspended in SuperAmp Lysis Buffer (Miltenyi Biotec) 
and frozen at -20˚C.  Frozen samples were sent to Miltenyi Biotec for PIQOR™ Mouse Stem 
Cell Microarray Analysis following Amplification.  The Miltenyi microarray and 
amplification services included RNA extraction, SuperAmp message amplification, 
microarray hybridization, and primary data analysis (determination of relative gene 
expression ratios).  
D. RESULTS AND DISCUSSION 
Generation of tEpoR-targeted ESC lines— We generated two different gene-targeted 
murine embryonic stem cell lines for the studies described in this report (Fig. 4-1).  The first 
was designed to express a nuclear-localized red-shifted Renilla reniformis green fluorescent 
protein (GFP), abbreviated hrGN (Stratagene).  The second cell line was engineered to 
express the same hrGN as well as a truncated erythropoietin receptor (tEpoR, described in 
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Chapter 1 of this dissertation) in tandem from the same locus, abbreviated GNtEpoR.  To 
promote ubiquitous stable transgene expression, the engineered constructs were targeted by 
homologous recombination to the hypoxanthine phosphoribosyltransferase (Hprt) locus, and 
each gene was controlled by a β-actin promoter element [232] and an SV40 polyadenylation 
signal [234].  (Additional benefits of Hprt targeting have been discussed in-depth in Chapter 
2 of this dissertation).  The hrGN fluorescent protein was chosen as a molecular marker for 
these studies because previous work by our collaborators has demonstrated that it is non-
toxic to ESC and does not alter the differentiation profile of the cells (S. Hatada, D. Ciavatta, 
and O. Smithies, personal communication).  Southern blotting was performed on genomic 
DNA of targeted clones to confirm correct targeting of the transgenic constructs, as shown in 
Figure 4-1B, left panel.  We also conducted reverse-transcriptase polymerase chain reaction 
(RT-PCR, Fig. 4-1B, right panel) to verify expression of the tEpoR in targeted clones.  Both 
the Southern blot and the RT-PCR results include a clone in which the GNtEpoR transgene 
was integrated in the forward orientation with respect to Hprt expression (GNtEpoR-for).  
Since all subsequent experiments in this report were conducted with the reverse-oriented 
GNtEpoR only, these cells will be referred to simply as GNtEpoR (rather than GNtEpoR-rev) 
for the sake of brevity.   
We assayed for hrGN expression by ultraviolet (UV) microscopy, and observed 
distinct foci of fluorescence, consistent with nuclear localization of the hrGN protein.  To 
further determine the percentage of cells expressing hrGN, we performed flow cytometric 
analysis on disaggregated cells from undifferentiated ESC as well as day 3 EB.  In both 
cases, at least 98% of the cells in culture demonstrated hrGN fluorescence (Fig. 4-1C, insets). 
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Figure 4-1 GFP and tEpoR transgene targeting to the Hprt locus of murine embryonic stem cells.   
A.) The constructs depicted in the box at left were targeted separately into the mutant Hprt locus of E14Tg2a 
ESC, as illustrated by the schematic on the right.  (Left) A 1.3-kb human β-actin promoter (hatched box) 
was used to drive expression of a nuclear-localizing red-shifted (Renilla reniformis) GFP (hrGN, green 
box) and a truncated erythropoietin receptor (tEpoR, red box); the small black rectangle marks the first 
exon of β-actin.  (Right) The untargeted Hprt locus in the ESC line (E14Tg2a).  The dashed line within 
parentheses represents the ~50 kb deletion that removes the Hprt promoter and first two exons.  The 
targeting construct includes one of the transgene constructs and the missing promoter and exons to correct 
the Hprt gene, flanked by homologous sequences to direct recombination.  Solid lines represent mouse 
sequences, and open lines indicate that in the correcting DNA the HPRT promoter (Phum) and its first exon 
are derived from the human HPRT gene.  Following HAT (hypoxanthine, aminopterine, thymidine) 
selection, only clones with a corrected Hprt locus, and thus an integrated transgene, will survive.  The small 
black bar shows the location of the target sequence for the probe used in Southern blotting, and “B” 
markers indicate recognition sites for BamHI. 
B.) (Left) The Southern blot resulting from BamHI digestion of targeted ESC DNA.  Untargeted (WT) ESC 
gave a 9.2-kb fragment; cells targeted with the GN or the GNtEpoR construct gave a 9.3-fragment; and the 
8.0-kb fragment was the result of integration of the GNtEpoR construct in the opposite orientation of that 
shown in panel A.  (Right) Reverse-transcriptase polymerase chain reaction (RT-PCR) was performed on 
mRNA from targeted ESC.  Comparison to a known tEpoR-expressing cell line (tEpoR +ctrl) showed that 
cells targeted with the GNtEpoR construct express tEpoR, while those targeted with the GN construct do 
not.  No reverse transcriptase was added to the (-RT ctrl) lanes, and H2O indicates a no-template control. 
C.) Phase contrast and fluorescent images of undifferentiated ESC (left) and day 3 embryoid bodies (EBs, 
right) from targeted ESC lines carrying the GNtEpoR transgenic construct.  The insets at the bottom are 
flow cytometric histograms showing GFP fluorescence in the entire populations from disaggregated 
cultures of undifferentiated ESC or day 3 EBs. 
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A tEpoR transgene enhances the hematovascular potential of ESC in vitro— We next 
examined the in vitro hematopoietic differentiation capacity of our targeted ESC lines using 
the protocol described by Keller et al [83].  Within this culture system, the bipotential 
precursor of hematopoietic and endothelial lineages develops between day 3.0 and 3.25 of 
EB differentiation.  Hemangioblast colonies (HB) derived from this precursor cell have an 
undifferentiated blast-cell morphology which can be readily distinguished from secondary 
embryoid bodies that develop in the cultures (Fig. 4-2A, schematic at left).  The precise 
kinetics and predictability of hemangioblast colony formation makes this culture system a 
good assay for hematovascular potential of different ESC lines.  Alternatively, a longer 
period of EB differentiation leads to the onset of primitive erythroid and early definitive 
hematopoiesis, allowing for assessment of multipotentiality of ESC lines (Fig. 4-2B, 
schematic at left).  In the case of our GN and GNtEpoR ESC, there was no difference in 
baseline HB colony formation between the two cell lines or in comparison to untargeted ESC 
(Fig. 4-2A, grey bars).  On the contrary, upon addition of erythropoietin (Epo) to the culture 
media, we saw a statistically significant 7.25-fold increase (p<0.01) in the ratio of HB to EB 
colonies from GNtEpoR ESC (8.63±1.11) as compared to untargeted cells (WT, 1.19±0.46) 
(Fig. 4-2A, red bars).  The slight increase in HB formation in GN ESC (2.54±0.75) was not 
significant and p<0.01 for GNtEpoR +Epo versus GN +Epo as well.  These results reinforce 
previous findings from our laboratory showing that in adult-type HSC from BM, ligand-
dependent activation of the tEpoR can expand HSC populations [46] and confer a 
repopulation advantage in competitive transplantation assays [47].  Furthermore, this 
demonstrated tEpoR-dependent expansion of in vitro hematovascular potential suggests that 
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the ability of a tEpoR transgene to provide a benign and controllable proliferation advantage 
to adult-type HSC may also be translated to HSC derived from ESC.   
 
Figure 4-2 Effect of tEpoR on hematopoietic development during in vitro differentiation of targeted ESC. 
A.) The hemangioblast assay was used to measure the hematovascular developmental potential of targeted ESC 
lines.  The schematic (left) illustrates the basic culture conditions for generating hemangioblasts from ESC, 
as described by Keller, et al [83].  Removal of leukemia inhibitory factor (LIF) and non-adherent culture 
dishes allows the cells to differentiate in the form of embryoid bodies (EBs).  Following three days of 
differentiation, the EBs are disaggregated and replated in methylcellulose medium with vascular 
endothelial growth factor (VEGF) and conditioned media from the embryonic endothelial cell line D4T.  
After approximately four days in culture, hemangioblast (HB) colonies form, which can be distinguished 
from secondary EBs morphologically.  Cells were plated in triplicate and the results from two different 
experiments were combined to generate the graph shown at right.  When erythropoietin (Epo) was added to 
the culture medium throughout the assay, GNtEpoR ESC showed a greater than 7-fold increase in 
hematovascular potential. 
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B.) Hematopoietic clonogenic potential of targeted ESC lines was tested with a similar in vitro assay, depicted 
at left.  Differentiation was initiated as described in panel A, and after 6 days, the EBs were disaggregated 
and replated in methylcellulose media containing several hematopoietic cytokines including Epo (complete 
media is described within the chapter).  After 5-7 days in culture, primitive and early definitive 
hematopoietic colonies were scored and the results are shown in the graph on the right.  The presence of the 
tEpoR transgene does not alter the hematopoietic lineage potential of targeted ESC, as compared to 
untargeted ESC (WT).  Colony types are defined as follows: EP, primitive erythroid; ED, definitive 
erythroid; E/Meg, erythroid/megakaryocyte; Meg, megakaryocyte; Mac, macrophage; G/M, 
granulocyte/macrophage; E/Mac, erythroid/macrophage; Mix, mixed-lineage colonies including 
granulocyte, erythroid, megakaryocyte and macrophage; EB, secondary embryoid body. 
 
Side Population sorting from day 3 EBs— Based on the carefully described kinetics 
of lineage development within the Keller EB culture system [83], we reasoned that the 
multipotential self-renewing HSC should arise in this system very close to the time of 
hemangioblast precursor formation.  We hypothesized that SP sorting of day 3 EBs 
differentiated via the Keller culture system would enrich for the hematopoietic or 
hemangioblastic progenitor cells known to reside within this structure.  Since SP sorting from 
day 3 EBs has not previously been reported, we first had to characterize this cell population.  
The Hoechst red versus Hoechst blue profile of day 3 (d3) EBs (Fig 4-3A) was very similar 
to that of Hoechst-stained whole bone marrow, although the percentage of cells falling within 
the SP gate was generally much higher that what is seen in bone marrow (average from 32 
SP sorts, 1.84%; range: 0.2%-5%; compared to reported BM SP of ~0.08% [3]).  The SP 
phenotype is dependent upon the ATP-binding cassette (ABC) transporter protein ABCG2 
[230], and enhanced by another member of this protein superfamily called ABCB1 [235, 
236] (formerly known as P-glycoprotein or MDR1).  We tested the effects of the ABCB1-
specific inhibitor verapamil and the pan-ABC transporter inhibitor reserpine [237] on the 
presence of the SP population from d3 EBs.  Verapamil had little to no effect on the 
appearance of the SP, but it was almost completely eradicated in the presence of reserpine 
(Fig. 4-3B).  We also stained the cells with antibodies to KIT and LY6A to compare their cell 
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surface phenotype to that of lineage-depleted bone marrow (a population enriched for HSC).  
While there were similar percentages of KIT+ and LY6A+ single-positive cells within both 
cell types, the day 3 EB-SP cells had a much smaller population of double-positive 
KIT+LY6A+ cells (Fig. 4-3C).  However, considering the fact that most of the events falling 
within the double-positive gate are only dimly positive for LY6A, it is possible that this 
result is partially an artifact of densely stained KIT+ cells bleeding into the LY6A channel.  
Accordingly, the reported percentage of lineage-negative KIT+LY6A+ in bone marrow is less 
that 1% [11].  This issue could be resolved through the use of fluorochromes with less 
spectral overlap. 
 
Figure 4-3 Characterization of Side Population (SP) sorted cells from GNtEpoR-targeted ESC. 
A.) Day 3 EBs from GNtEpoR-targeted ESC were disaggregated with trypsin, then incubated with 5μg/mL 
Hoechst 33342.  Flow cytometric emission monitoring at both 405 nm and 670 nm allows for selection of 
the Side Population of cells (SP cells, gated, left panel), which exclude the Hoechst dye.  The right panel 
demonstrates a post-sort assessment of the purity of the sorted population. 
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B.) Disaggregated day 3 EBs were incubated with Hoechst 33342 in the presence of verapamil or reserpine, 
two multidrug transporter inhibitors with different molecular targets.  Verapamil had only a minimal effect 
on the presence of the Side Population, but this population was eliminated in the presence of reserpine. 
C.) (Left) Following Hoechst dye incubation, day 3 EB cells were stained with antibodies to the common HSC 
markers KIT and LY6A.  The histogram is gated on the Side Population, and the percentage of cells stained 
by each marker is indicated in the respective quadrants.  (Right) Lineage-depleted bone marrow (BM) was 
stained with the same antibodies to serve as a reference population. 
 
The hrGN transgene is not sufficient for tracking engraftment of ESC-derived cells— 
To determine the ability of day 3 EB-SP cells to engraft and repopulate in vivo, we used the 
conditioned newborn transplant model described by Yoder et al. [70], and chose NOD.scid 
mice as our recipients in order to diminish the chance of graft rejection (Fig. 4-4A).  We also 
transplanted some recipients with unfractionated cells from hemangioblast cultures to 
determine if these more mature blast colony cells could demonstrate stem cell properties in 
vivo (Fig. 4-4B).  Initially, we assayed for donor cell engraftment by looking for GFP 
expression since both cell lines used to generate grafts were targeted with hrGN.  However, 
after approximately 90% of the transplanted mice had reached the four week time point (with 
no evidence of engraftment as assayed by GFP expression), we concluded that the hrGN 
transgene may not be sufficient for tracking engraftment in this model. 
Despite strong GFP fluorescence in immature cells from our targeted ESC (Fig. 4-
4D), it is possible that some transcriptional silencing event took place as the cells 
differentiated to hematopoietic lineages.  Tandem arrays of transgenes have been shown to 
generate regions of heterochromatin [238], which is one possible explanation for the loss of 
GFP signal.  Alternatively, since the blood was fixed after collection and run through the 
flow cytometer at a later timepoint, it is possible that the fluorescence signal was lost prior to 
flow analysis.  However, analysis of fresh (non-fixed) blood samples from mice known to be 
 78 
engrafted (as detected by H2Kb expression, see below) also did not show GFP fluorescence, 
arguing for actual loss of hrGN expression rather than extinction of fluorescent signal.   
 
Figure 4-4 Transplantation scheme for ESC-derived cell populations injected into neonatal mice. 
In utero conditioned NOD.scid neonates were used as recipients for ESC-derived hematopoietic stem and 
progenitor cells.  The center of the figure depicts the developmental timeline of the recipient mouse.  Timed 
pregnancies were set up and pregnant dams were injected intra-peritoneally with busulfan (BU, 15.5-22 mg/kg) 
two days and one day before delivery (day 18 and day 19 post-coitus).  Within 24 hours of birth, recipient pups 
were injected via the facial vein with ESC-derived cells.  After transplantation, recipient mice were bled every 
four to six weeks to assay for donor cell engraftment by flow cytometric analysis.  (A) For EB-SP transplants, 
day 3 EBs were disaggregated and incubated with Hoechst 33342, then Side Population cells were sorted and 
injected into recipients.  (B) For hemangioblast transplants, day 3 EBs were disaggregated and replated in 
methylcellulose media with VEGF and D4T, then after 4-6 days in culture cells were harvested for 
transplantation.  (C) Peripheral blood of transplant recipients was analyzed by flow cytometry to assess 
engraftment.  At the first (4 week) timepoint, blood was analyzed for GFP fluorescence.  However, due to 
concerns over inadequate GFP expression from a single copy transgene, peripheral blood at all subsequent 
timepoints was stained for H2Kb, the class I major histocompatibility complex (MHC) antigen expressed only 
on donor cells; recipient cells express the H2Kd isotype of this gene.  Blood from mice that showed donor cell 
engraftment after 12 weeks was also stained with antibodies to specific lymphoid and myeloid markers.  (D) 
Representative histograms show GFP and H2Kb expression on GNtEpoR-targeted ESC (left) and day 3 EBs 
(right). 
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Transplantable Hematopoietic Progenitors from Side Population Sorted day 3 EBs 
and Unfractionated Hemangioblast Cultures— Following the conclusion that the hrGN 
transgene was insufficient for cell tracking, we converted to H2Kb detection as a marker for 
engraftment since the ESC lines (derived from 129 mice) express this major 
histocompatibility complex (MHC) isotype, while the recipient NOD.scid mice express the 
H2Kd isotype.  At each time point assayed, a non-transplanted NOD.scid mouse was also 
bled to serve as a control for background nonspecific H2Kb+ staining (Fig. 4-5C).  Using the 
H2Kb detection method, we saw low to moderate levels of ESC-derived hematopoietic 
engraftment in all transplant groups.  A small number of mice showed high levels (>30%) of 
engraftment after 3 months, but these mice did not cluster to any specific graft type.  The 
complete engraftment results are presented in the charts in Figure 4-5A and B.  Only mice 
that showed at least 1% donor chimerism (above background) on at least one time point were 
included on the charts.  Recipient mice that never showed evidence of engraftment were not 
included on the charts, but a summary of all mice transplanted can be seen in Table 4.2.   
In all surviving mice that showed engraftment after 12 weeks, we also tested for the 
presence of specific lymphoid (CD3 and B220) and myeloid (Gr-1) markers on H2Kb+ 
donor-derived cells.  Flow cytometric analysis of peripheral blood from a representative 
engrafted mouse is shown in Figure 4-5C.  The presence of both lymphoid and myeloid 
donor-derived cells after four months in every transplant group we tested indicates that SP-
sorted cells from day 3 EBs as well as cells from HB cultures contain long-term repopulating 
multilineage hematopoietic stem or progenitor cells.  Rigorous definition of a stem cell 
requires evidence of self-renewal as assayed by secondary transplantation.  Secondary 
transplants of bone marrow from engrafted primary recipients into irradiated secondary adult 
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hosts have been done, but at the time of dissertation preparation had not yet reached a time 
point for analysis.   
 
Figure 4-5 Engraftment of ESC-derived hematopoietic stem/progenitor cells. 
Cells were prepared and transplanted as described in Figure 4-4.  In some transplants (+Epo), erythropoietin 
was either added to the culture medium or injected into recipients following transplantation (or both).  Only 
mice showing at least 1% peripheral blood donor cell chimerism on at least one timepoint are included on the 
graphs.  (A) EB-SP Cell Transplants, (B) Hemangioblast Cell Transplants 
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C) Representative flow cytometric profile of peripheral blood from a mouse with multilineage ESC-derived 
engraftment.  (Left) The H2Kb+ gate was set based on antibody-stained blood from a NOD.scid mouse that did 
not receive a transplant.  (Middle, Right) Only the H2Kb+ gated cells were included on the far right histogram, 
which shows H2Kb+ (ESC-derived) cells that stain positively for markers of both the lymphoid (CD3+ for T 
cells and B220+ for B cells) and myeloid (Gr-1+) lineages. 
 
Limitations of the transplant model— It is notable that the transplant procedure itself 
is rather hard on the mice as well as technically challenging, so many mice died before 
weaning and could not be included in the analysis.  Furthermore, while the NOD.scid mouse 
is a good choice as a recipient in regards to avoidance of graft rejection, these mice have a 
very high incidence of thymic lymphomas [239], resulting in reduced lifespan (mean: 8.5 
months).  The occurrence of thymic lymphomas may have also been exacerbated in our 
transplant model by in utero busulfan conditioning.  Indeed, a significant number of the mice 
(both engrafted and non-engrafted) harvested at the end of the transplant experiment (16-19 
weeks post-transplant) were found to have thymic lymphomas.  It is likely that many of the 
mice that died during the course of the experiment also harbored thymic lymphomas that may 
have been the cause of death, but the bodies were not autopsied, so we cannot be certain.  In 
any case, interpretation of survival data as it relates to graft type is not useful in this 
transplant model because of the high background rate of death related to thymic lymphoma 
development. 
Teratoma formation from transplanted ESC-derived HB cells— There were several 
mice that developed teratomas at the site of injection within 1-2 months following 
transplantation (see Table 4.1).  These tumors were removed, preserved, sectioned, and 
examined histologically to confirm the presence of tissue types from all three germ layers.  
Notably, for transplants derived from the GNtEpoR ESC line, all of the mice that developed 
teratomas were from the unfractionated HB transplant groups.  This result is not surprising 
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since the appearance of secondary embryoid bodies alongside HB colonies in these cultures 
indicates the persistent presence of undifferentiated ESC.  It is somewhat surprising, 
however, that none of the GNtEpoR EB-SP cell recipients developed teratomas, since day 3 
EBs are also known to harbor undifferentiated ESC.  The lack of teratoma formation in the 
EP-SP group suggests that the SP sorting procedure excludes undifferentiated ESC at this 
stage of differentiation.  However, in transplants derived from the GN ESC line, there were a 
small number of mice that developed teratomas from the EB-SP sorted cells.  It is important 
to point out that the SP profile of the cells that gave rise to these teratomas was distinctly 
different from the majority of the SP profiles from day 3 EBs.  Specifically, in the case of the 
teratoma-forming cells the SP percentage was extremely high (~4.5%) as compared to most 
SP sorts and the overall distribution of cells was shifted, resulting in an unclear demarcation 
between SP and non-SP cells.  Thus, a critical detail about SP sorting is that dye efflux is a 
dynamic process which marks stem cell activity, but does not define a hematopoietic stem 
cell.  So while SP sorting appears to be a highly successful method for elimination of 
undifferentiated cells, the ultimate goal of therapeutic application of these cells will require a 
more direct method of elimination of teratoma-forming cells.   
Table 4.1 Teratoma formation in ESC-derived transplant recipients 
Graft Genotype Graft Phenotype 
Teratoma, Teratocarcinoma, or 
Carcinosarcoma Formation 
(# out of total transplanted) 
GNtEpoR EB-SP 0/122 
GN EB-SP 6/112 
GNtEpoR HB 10/46 
GN HB 0/17 
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Effect of the tEpoR transgene on engraftment of ESC-derived hematopoietic 
progenitor cells— To test the ability of the tEpoR transgene to expand hematopoietic 
progenitors or facilitate engraftment of ESC-derived cells in vivo, we included Epo either in 
the culture media during cell differentiation, or administered it as subcutaneous injections 
into recipient mice following transplantation.  Ligand-dependent activation of the transgene 
did not appear to affect the level of chimerism in recipient mice (Figure 4-5).  On the other 
hand, the percentage of mice that showed some level of engraftment was higher in 
GNtEpoR-derived transplants with Epo as compared to those without Epo (Table 4.2).  This 
trend was not evident in the GN-derived transplants, suggesting that the tEpoR may have a 
positive effect on transplantation efficiency from ESC-derived cells, consistent with the idea 
of tEpoR-dependent HSC expansion in the transplanted populations.   
Table 4.2 Engraftment of ESC-derived hematopoietic stem/progenitor cells. 
Graft 
Genotype 
Graft 
Phenotype 
Total 
Transplants 
No. of Pups Analyzed 
(survived to weaning) No. Engrafted (%) 
GNtEpoR EB-SP 122 53 
18 +Epo 10 (56%) +Epo 
35 NoEpo 14 (40%) No Epo 
GN EB-SP 112 35 
13 +Epo 4 (31%) +Epo 
22 NoEpo 8 (36%) No Epo 
GNtEpoR HB 46 38 
16 +Epo 12 (75%) +Epo 
22 NoEpo 5 (23%) No Epo 
GN HB 17 15 
10 +Epo 6 (60%) +Epo 
5 NoEpo 4 (80%) No Epo 
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Microarray Analysis to Compare GNtEpoR EB-SP to Standard Adult-Type and 
Embryonic-Type HSC— The ontogeny of the hematopoietic system illustrates a kind of 
spectrum of hematopoietic progenitor cell phenotypes.  At the far left end of the spectrum is 
the YS HSC, which is the most primitive and the earliest to arise in the developing embryo.  
At the opposite end of this spectrum is the BM HSC, which is established last in 
development but maintains the animal throughout adult life.  While the embryonic stem cell 
is obviously at the left end of this spectrum, it is unclear precisely where a hematopoietic 
stem cell differentiated from the ESC would land.  Therefore, we conducted a molecular 
analysis (via microarray) of the hematopoietic stem/progenitor population we have identified 
through SP sorting of day 3 EBs.  We chose a stem cell-focused microarray containing 912 
genes related to the phenotype and function of stem cells derived from all three germ layers 
as well as undifferentiated ESC.  The genes included in the array were assembled from 
literature screens, gene expression profiling data and bioinformatics-based homology 
screens.  The gene expression profiles of our EB-SP HSC were compared back to cell 
populations at either end of the HSC phenotypic spectrum – namely, adult-type lineage-
depleted BM cells and embryonic-type YS cells from day 9.5 embryos.  A summary of gene 
expression changes is shown in Table 4.3.  For all comparisons drawn, the vast majority of 
genes in the array were not significantly changed between the various HSC populations.  
However, there were a large number of stem cell genes that were significantly (>1.7-fold) up- 
or down-regulated in EB-SP cells with respect to expression in either adult-type BM HSC or 
embryonic-type YS HSC.  Upon further study, these differentially regulated genes may prove 
useful in defining the molecular phenotype of transplantable HSC derived from ESC. 
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Table 4.3 Summary of gene expression results from the stem cell microarray 
EB-SP Sample 
No. of genes with 
significant change 
in expression 
(>1.7-fold) 
Up-regulated 
No. of genes 
unchanged 
No. of genes 
that could not 
be scored Down-regulated 
Reference Sample: Lineage-Depleted Bone Marrow (Adult-type HSC) 
GNtEpoR No Epo 108 
74 
783 19 
34 
GNtEpoR +Epo 144 
96 
737 29 
48 
Reference Sample: day 9.5 Yolk Sac (Embryonic-type HSC) 
GNtEpoR No Epo 63 
20 
815 32 
43 
GNtEpoR +Epo 82 
45 
794 34 
37 
 
Genes whose expression was similarly changed in EB-SP differentiated both with and 
without Epo are of particular interest in this study, as they may include a set of genes specific 
to ESC-derived HSC (see Fig. 4-6A).  Furthermore, genes whose expression was up- or 
down-regulated uniquely in the EB-SP +Epo sample may provide insight into the molecular 
mechanism of HSC expansion we observed in the transplants conducted with these cells.  We 
found that differential gene expression across all genes assayed was much more pronounced 
in the comparison of EB-SP to Lin-depleted BM than it was in the comparison of EB-SP to 
YS (Fig. 4-6B, comparison of solid bars to hatched bars).  As a rough estimation, this would 
suggest that EB-SP cells are more closely related to the YS HSC than they are to the BM 
HSC.  This finding may have been predicted based on the close relationship between YS 
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hematopoiesis and hematopoietic development within the Keller et al. culture system [83, 92, 
93]. 
 
Figure 4-6 Summary of microarray results comparing GNtEpoR EB-SP to Lin-depleted BM and YS 
A Stem Cell-Focused microarray analysis (912 genes) was conducted comparing GNtEpoR EB-SP cells 
(differentiated with or without Epo) to adult-type (Lin-depleted BM) and embryonic-type (YS) HSC 
populations.  (A) The overlapping areas in the Venn diagrams indicate the number of genes whose expression 
changed significantly (>1.7-fold) in both GNtEpoR EB-SP samples (i.e., those differentiated with and without 
Epo).   
(B) The chart summarizes the number of genes that were significantly up- or down-regulated (>1.7-fold change) 
for each comparison that was drawn.  Solid bars represent comparison to Lin-depleted BM cells and hatched 
bars represent comparison to YS cells.  
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The microarray analysis we conducted included stem cell relevant genes from many 
different tissue types.  However, our primary interest for the purposes of the current study 
was to focus on genes relevant to the hematopoietic system or to general stem cell properties, 
such as cell cycle quiescence.  In addition, since the long-term goal of HSC isolation from 
ESC is to characterize cells capable of engraftment in adult settings, we concentrated on the 
differences between EB-SP and BM (setting aside EB-SP versus YS results for future 
studies).  Accordingly, upon closer inspection of the microarray results comparing EB-SP to 
BM, we were intrigued by significant differential regulation of genes implicated in HSC 
homing (CXCR4 [240]), HSC quiescence (ITGB3 [241], CDKN1B [242]), cell cycle/aging 
(CDC42 [243], BUB3 [244]), and hematopoietic growth factor signaling (KIT [245], PAK1 
[246]) in the EB-SP sorted cells (Summarized in Table 4.4).  We are currently in the process 
of confirming these results by real-time RT-PCR so that we may further focus our studies on 
genes that may define the difference between ESC-derived HSC and adult-derived BM HSC. 
Table 4.4 Genes of interest from stem cell microarray comparison of EB-SP to Lin-depleted BM 
Genes of Interest (Fold Change wrt Lin-depleted BM) 
UPregulated DOWNregulated 
KIT 
+E:  39.12 
TAL1 
+E:  -2.17 
NoE:  23.88 NoE:  -1.54 (ns) 
ITGB3 
+E:  12.02 
CDKN1B 
+E:  -2.33 
NoE:  20.31 NoE:  -1.89 
CXCR4 
+E:  19.7 
BUB3 
+E:  -2.86 
NoE:  20.69 NoE:  -2.70 
CDC42 
+E:  18.65   
NoE:  18.62   
PAK1 
+E:  2.08   
NoE:  1.99   
 88 
E. FUTURE DIRECTIONS 
A microarray experiment is, by design, much more of a beginning than an ending.  
Preliminary analysis of our microarray results has revealed many exciting possibilities for 
exploration of the fundamental differences between embryonic- and adult-type HSC.  The 
most pressing steps in further analysis at this point are: (1) confirmation of microarray results 
to validate the findings, and (2) analysis of the secondary transplants that we have conducted 
from the EB-SP cells.  In the absence of engraftment in secondary transplants, EB-SP cells 
do not meet the strictest definition of HSC and can only be considered long-term 
repopulating hematopoietic progenitor cells.  In the case of failed secondary transplants, the 
preliminary microarray results pertaining to cell cycle, self-renewal, and aging will be of 
particular interest for future studies.   
If, on the other hand, we do see evidence of engraftment in secondary transplants, the 
microarray results, once confirmed, may be especially informative in translating our findings 
to an adult transplant model.  We did transplant a small number (<30) of irradiated adult 
recipients with EB-SP cells at the same time that we conducted the experiments described in 
this chapter, and saw no evidence of engraftment over the four month analysis period (data 
not shown).  This result mirrors the obstacles encountered in early attempts to transfer YS 
HSC to adult hosts [247].  Nonetheless, YS cells have been recently shown to contribute to 
adult hematopoiesis [71].  Likewise, in-depth molecular analysis of EB-SP cells compared to 
BM HSC may reveal the mechanistic basis of the lack of adult repopulation.  Given the 
relative ease of genetic manipulation of ESC, it may be possible to alter any genes uncovered 
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in this analysis in order to facilitate the ultimate goal in these studies: adult engraftment by 
ESC-derived cells.   
 
Chapter 5 PERSPECTIVES AND FUTURE DIRECTIONS 
One of the great advances in modern medicine came with the advent of hematopoietic 
stem cell transplantation to alleviate or cure many of the diseases that affect the 
hematopoietic system.  Over the past several decades, HSC transplantation has developed 
into a common and often successful treatment modality; however, there are still significant 
obstacles that must be overcome for this therapy to reach its full potential.  First, HSC are a 
rare population in bone marrow, umbilical cord blood and peripheral blood, which are the 
only currently available sources of this cell type.  Second, despite many years of research, 
attempts to expand HSC have been largely unsuccessful, commonly resulting in loss of self-
renewal, multipotentiality or homing ability of the cells.  Third, there are significant 
immunological hurdles in HSC transplantation, including allograft rejection, lack of available 
MHC-matched grafts, or post-transplant manifestations of graft-versus-host disease.  Finally, 
the toxicity of currently available pre-transplant conditioning regimens is prohibitive for the 
application of HSC transplantation to non-life-threatening diseases. 
Embryonic stem cells represent a potential alternative source of transplantable 
hematopoietic cells which may circumvent each of the aforementioned obstacles in HSC 
transplantation.  There are many distinct advantages to the ESC system, including unlimited 
numbers of cells that maintain potency in culture, the ability to control differentiation to a 
particular tissue type, and relative ease of genetic manipulation, allowing for correction of 
genetic defects or introduction of therapeutic transgenes.  Nevertheless, there are several key 
criteria which must be rigorously met before therapeutic transplantation of ESC-derived cells 
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can become a reality.  Following induction of hematopoietic differentiation, there must be an 
efficient and robust protocol for isolation of the self-renewing, long-term, multilineage stem 
cell population which maintains the ability to engraft upon transplantation.  Furthermore, 
there must be a reliable method for removal of any remaining undifferentiated cells which 
could give rise to teratomas.   
The findings presented in this dissertation provide progress toward the ultimate goal 
of isolating transplantable hematopoietic stem cells differentiated from embryonic stem cells.  
In a mouse model system, we have demonstrated long-term multilineage hematopoietic 
engraftment from SP sorted day 3 embryoid body cells (EB-SP) as well as unfractionated 
hemangioblast culture cells (differentiated using the Keller method [83]).  In the case of the 
EB-SP transplants, we achieved engraftment from the lowest number of ESC-derived cells 
that has been reported to date (range: 2.5-20x103 cells transplanted), suggesting that SP 
sorting significantly enriches for the stem cell population.  Furthermore, prior to our study, 
the shortest differentiation culture time that has been reported to generate engraftable cells is 
four days [116], with culture time from all other similar studies ranging from 5-30 days (see 
Table 1.2).  Minimal culture time is preferable for any proposed therapeutic application since 
the risk of contamination of the graft increases with the time in culture, thereby increasing 
the risks to the patient.  Other groups attempted transplants from early stage EBs, but no 
engraftment results could be reported because all mice developed teratomas; thus another 
important advance in our study is the near complete elimination of teratoma formation by SP 
sorting from day 3 EBs.  In addition to prolonged culture time, all but one of the published 
reports on ESC-derived cells in last 10 years have required enforced overexpression of 
transcription factor or signaling molecule genes to achieve hematopoietic engraftment.  The 
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viral constructs used to introduce these genes, as well as the nature of the genes themselves 
are concerning for therapeutic application due to possible risk of malignant transformation.  
It is highly encouraging that, in our study, we were able to isolate a population of ESC-
derived cells that could engraft under normal conditions (i.e. without enforced gene 
expression).  One last point that makes our study unique is that the cells were transplanted 
into neonatal recipient mice.  While adult engraftment will be necessary for any future 
therapeutic application, our demonstrated successful engraftment in neonates may reveal 
important characteristics of ESC-derived cells related to homing and engraftment abilities. 
The next stage of the research presented here will focus on refining the selection 
methods for transplantable hematopoietic cells from ESC, developing further methods for 
reliable elimination of teratoma-forming cells, and improving expansion of the stem cell 
population.  We intend to test combined positive/negative selection protocols that are 
designed to positively select transplantable hematopoietic stem cells (or their developmental 
precursors) and negatively select undifferentiated cells in the ESC differentiation culture.  
We have an ongoing collaboration with Dr. S. Hatada, who developed an elegant fluorescent 
protein based positive/negative selection system for gene-targeted cells which may be 
adaptable to our goals [248].  The positive selection may be achieved by a combination of SP 
sorting and the lineage-restricted fluorescent gene sorting described in Chapter 2 of this 
dissertation.  Necessary adjustments to the previously described methods will be either the 
inclusion of additional regulatory elements from the Scl locus or the use of gene regulatory 
elements from a different gene whose expression is unique to early hematopoietic 
development, such as Tmtsp [249].  Similar lineage-restricted expression methods may be 
useful for negative selection of cells expressing genes unique to undifferentiated ESC. 
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